<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Microorganisms</journal-id><journal-id journal-id-type="iso-abbrev">Microorganisms</journal-id><journal-id journal-id-type="pmc-domain-id">3054</journal-id><journal-id journal-id-type="pmc-domain">microorg</journal-id><journal-id journal-id-type="publisher-id">microorganisms</journal-id><journal-title-group><journal-title>Microorganisms</journal-title></journal-title-group><issn pub-type="epub">2076-2607</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7762175</article-id><article-id pub-id-type="pmcid-ver">PMC7762175.1</article-id><article-id pub-id-type="pmcaid">7762175</article-id><article-id pub-id-type="pmcaiid">7762175</article-id><article-id pub-id-type="pmid">33291260</article-id><article-id pub-id-type="doi">10.3390/microorganisms8121936</article-id><article-id pub-id-type="publisher-id">microorganisms-08-01936</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>T Cell Immunity and the Quest for Protective Vaccines against <italic toggle="yes">Staphylococcus aureus</italic> Infection</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Armentrout</surname><given-names initials="EI">Erin I.</given-names></name><xref ref-type="aff" rid="af1-microorganisms-08-01936">1</xref><xref ref-type="aff" rid="af2-microorganisms-08-01936">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="GY">George Y.</given-names></name><xref ref-type="aff" rid="af3-microorganisms-08-01936">3</xref><xref ref-type="aff" rid="af4-microorganisms-08-01936">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martins</surname><given-names initials="GA">Gisl&#226;ine A.</given-names></name><xref ref-type="aff" rid="af5-microorganisms-08-01936">5</xref><xref ref-type="aff" rid="af6-microorganisms-08-01936">6</xref><xref ref-type="aff" rid="af7-microorganisms-08-01936">7</xref><xref rid="c1-microorganisms-08-01936" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-microorganisms-08-01936"><label>1</label>Lung Institute, Cedars-Sinai Medical Center (CSMC), Los Angeles, CA 90048, USA; <email>erin.armentrout@cshs.org</email></aff><aff id="af2-microorganisms-08-01936"><label>2</label>Division of Pulmonary and Critical Care Medicine, CSMC, Los Angeles, CA 90048, USA</aff><aff id="af3-microorganisms-08-01936"><label>3</label>Collaborative to Halt Antibiotic-Resistant Microbes, University of California, San Diego, La Jolla, CA 92161, USA; <email>gyliu@health.ucsd.edu</email></aff><aff id="af4-microorganisms-08-01936"><label>4</label>Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA</aff><aff id="af5-microorganisms-08-01936"><label>5</label>F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute (IBIRI), CSMC, Los Angeles, CA 90048, USA</aff><aff id="af6-microorganisms-08-01936"><label>6</label>Department of Biomedical Sciences, Research Division of Immunology, CSMC, Los Angeles, CA 90048, USA</aff><aff id="af7-microorganisms-08-01936"><label>7</label>Department of Medicine, Division of Gastroenterology, CSMC, Los Angeles, CA 90048, USA</aff><author-notes><corresp id="c1-microorganisms-08-01936"><label>*</label>Correspondence: <email>martinsg@csmc.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2020</year></pub-date><volume>8</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">371454</issue-id><elocation-id>1936</elocation-id><history><date date-type="received"><day>10</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>30</day><month>11</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>12</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>26</day><month>12</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2020-12-26 00:45:18.420"><day>26</day><month>12</month><year>2020</year></date></event></pub-history><permissions><copyright-statement>&#169; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="microorganisms-08-01936.pdf"/><abstract><p><italic toggle="yes">Staphylococcus aureus</italic> is a wide-spread human pathogen, and one of the top causative agents of nosocomial infections. The prevalence of antibiotic-resistant <italic toggle="yes">S. aureus</italic> strains, which are associated with higher mortality and morbidity rates than antibiotic-susceptible strains, is increasing around the world. Vaccination would be an effective preventive measure against <italic toggle="yes">S. aureus</italic> infection, but to date, every vaccine developed has failed in clinical trials, despite inducing robust antibody responses. These results suggest that induction of humoral immunity does not suffice to confer protection against the infection. Evidence from studies in murine models and in patients with immune defects support a role of T cell-mediated immunity in protective responses against <italic toggle="yes">S. aureus</italic>. Here, we review the current understanding of the mechanisms underlying adaptive immunity to <italic toggle="yes">S. aureus</italic> infections and discuss these findings in light of the recent <italic toggle="yes">S. aureus</italic> vaccine trial failures. We make the case for the need to develop anti-<italic toggle="yes">S. aureus</italic> vaccines that can specifically elicit robust and durable protective memory T cell subsets.</p></abstract><kwd-group><kwd><italic toggle="yes">Staphylococcus aureus</italic></kwd><kwd>vaccine</kwd><kwd>antibodies</kwd><kwd>T cell-mediated immunity</kwd><kwd>tissue-resident memory T cells</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-microorganisms-08-01936"><title>1. Introduction</title><p><italic toggle="yes">Staphylococcus aureus</italic> is a Gram-positive facultative anaerobe that is a leading cause of bacterial infections worldwide. It is especially problematic in hospital settings where <italic toggle="yes">S. aureus</italic> is the most common cause of post-operative infections [<xref rid="B1-microorganisms-08-01936" ref-type="bibr">1</xref>] with costs that can exceed $90,000 per case [<xref rid="B2-microorganisms-08-01936" ref-type="bibr">2</xref>]. In community settings, <italic toggle="yes">S. aureus</italic>, which includes both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains, is the most frequent cause of skin and soft tissue infection. The distinction between healthcare-associated (HA-MRSA) and community-associated <italic toggle="yes">S. aureus</italic> (CA-MRSA) infections is important because the prevalence of antibiotic resistance genes and certain virulence factors vary between the two types. This difference can affect infection severity and antibiotic management [<xref rid="B3-microorganisms-08-01936" ref-type="bibr">3</xref>]. Overall, it is estimated that MRSA infections cause an annual burden of up to $13.8 billion in the US alone [<xref rid="B4-microorganisms-08-01936" ref-type="bibr">4</xref>].</p><p><italic toggle="yes">S. aureus</italic> has predilection for a broad range of tissues, which leads to manifestations such as folliculitis as well as life-threatening infections including pneumonia, endocarditis, osteomyelitis, and sepsis. The pathogen causes recurrent infections, suggesting that humans do not naturally develop long-lasting robust protective immunity against this bacterium. <italic toggle="yes">S. aureus</italic> also commonly colonizes human skin and mucosal surfaces, particularly in upper airways with some strains also showing a preference for the gastrointestinal tract [<xref rid="B5-microorganisms-08-01936" ref-type="bibr">5</xref>]. It is estimated that about 30% of the population [<xref rid="B6-microorganisms-08-01936" ref-type="bibr">6</xref>] is colonized with <italic toggle="yes">S. aureus</italic> and that colonization can occur as early as the neonatal period [<xref rid="B7-microorganisms-08-01936" ref-type="bibr">7</xref>]. Colonization with <italic toggle="yes">S. aureus</italic> in healthy individuals is a risk factor for future staphylococcal infections by serving as the infectious source [<xref rid="B8-microorganisms-08-01936" ref-type="bibr">8</xref>] and possibly by attenuating the host immune response against the pathogen.</p><p><italic toggle="yes">S. aureus</italic> was first discovered in 1880 when Sir Alexander Ogston isolated the bacterium from an infected wound of a patient. The mortality rate for moderate to severe <italic toggle="yes">S. aureus</italic> infection was 80% in the pre-antibiotic era [<xref rid="B9-microorganisms-08-01936" ref-type="bibr">9</xref>] and came down to 20% after the introduction of penicillin [<xref rid="B10-microorganisms-08-01936" ref-type="bibr">10</xref>]. However, with each newly-introduced antibiotic, <italic toggle="yes">S. aureus</italic> promptly gained resistance and there is evidence that MRSA strains are associated with higher morbidity and mortality rates compared to their antibiotic susceptible counterparts [<xref rid="B11-microorganisms-08-01936" ref-type="bibr">11</xref>].</p><p>The high disease burden and spread of antibiotic-resistant strains that led to antibiotic overuse has further highlighted the need for vaccination against <italic toggle="yes">S. aureus</italic>. Over the past decades and coinciding with the emergence of CA-MRSA, there has been a significant effort to develop anti-staphylococcal vaccines. Unexpectedly, to this date, every vaccine developed against <italic toggle="yes">S. aureus</italic> has failed in clinical trials, despite their demonstrated efficacy in animal models [<xref rid="B12-microorganisms-08-01936" ref-type="bibr">12</xref>,<xref rid="B13-microorganisms-08-01936" ref-type="bibr">13</xref>,<xref rid="B14-microorganisms-08-01936" ref-type="bibr">14</xref>]. There is no consensus on why the vaccines have failed. Here, we review the immune response to <italic toggle="yes">S. aureus</italic> infection as it relates to vaccination and the failed vaccines, while making a case for alternative approaches to address this bottleneck to solving the staphylococcal health burden.</p></sec><sec id="sec2-microorganisms-08-01936"><title>2. Previous and Ongoing Human <italic toggle="yes">S. aureus</italic> Vaccine Trials</title><p>There have been numerous attempts to create vaccines against <italic toggle="yes">S. aureus</italic>, which can be divided into two different approaches: Transfer of antibodies specific to staphylococcal antigens (passive immunization) or vaccination with recombinant antigens with the main goal of generating protective antibody responses (active immunization). These strategies either targeted surface proteins to promote the opsonophagocytic killing of <italic toggle="yes">S. aureus</italic> or targeted toxins to reduce cytolytic damages and immunopathology. <italic toggle="yes">Staphylococcal</italic> surface antigens targeted in vaccines include Clumping factor A and B (ClfA and ClfB), Iron-regulated surface determinant A and B (IsdA and IsdB), Capsular Polysaccharide 5 and 8 (CP5 and CP8), Serine&#8211;aspartate repeat protein D and E (SdrD and SdrE), and Manganese binding protein C (MntC). These proteins were selected on the basis of their high level of conservation across <italic toggle="yes">S. aureus</italic> strains [<xref rid="B15-microorganisms-08-01936" ref-type="bibr">15</xref>]. Commonly selected <italic toggle="yes">S. aureus</italic> toxins included the Panton-Valentine Leukocidin (PVL, comprised of LukS-PV and Luk-PV), staphylococcal enterotoxin A and B (SEA and SEB), and &#945;-toxin (Hla). Early vaccine studies focused on single antigens, whereas later studies targeted multiple staphylococcal antigens aiming to increase vaccine efficacy [<xref rid="B15-microorganisms-08-01936" ref-type="bibr">15</xref>,<xref rid="B16-microorganisms-08-01936" ref-type="bibr">16</xref>].</p><p>None of the vaccination or antibody transfer strategies clinically tested so far (recently reviewed by Redi et al. and Fowler &amp; Proctor [<xref rid="B13-microorganisms-08-01936" ref-type="bibr">13</xref>,<xref rid="B14-microorganisms-08-01936" ref-type="bibr">14</xref>]) have shown protection or lasting protection against <italic toggle="yes">S. aureus</italic> infection in patients (<xref rid="microorganisms-08-01936-t001" ref-type="table">Table 1</xref> and <xref rid="microorganisms-08-01936-t002" ref-type="table">Table 2</xref>) and the underlying reasons remain unclear. It has been suggested that the reasons underlying these failures range from the wrong choice of target antigens and adjuvants, to particularities of the study designs, target population inadequacy, and the notion that the murine experimental models of <italic toggle="yes">S. aureus</italic> infection used in pre-clinical vaccine studies likely do not fully reproduce the features of the human immune response to <italic toggle="yes">S. aureus</italic>. Regarding the latter, one important aspect to consider is the difference in colonization with <italic toggle="yes">S. aureus</italic> between mice and humans. In contrast to humans, which can be colonized with <italic toggle="yes">S. aureus</italic> early in life [<xref rid="B7-microorganisms-08-01936" ref-type="bibr">7</xref>], mice are not colonized or are colonized at a lower frequency [<xref rid="B17-microorganisms-08-01936" ref-type="bibr">17</xref>,<xref rid="B18-microorganisms-08-01936" ref-type="bibr">18</xref>].</p><p>Nine different clinical trials testing passive immunization made it to phase II and III (<xref rid="microorganisms-08-01936-t001" ref-type="table">Table 1</xref>). However, the great majority of these trials showed that antibody administration had no effect or offered only moderate protection in comparison to placebo treatment. Two studies utilized human polyclonal antibodies against CP5 and CP8, which was effective in shortening the length of stay for patients with bacteriemia but not in preventing invasive infection in neonates [<xref rid="B19-microorganisms-08-01936" ref-type="bibr">19</xref>,<xref rid="B20-microorganisms-08-01936" ref-type="bibr">20</xref>]. Another study tested if donor derived antibodies against ClfA from <italic toggle="yes">S. aureus</italic> and SdrG from <italic toggle="yes">Staphylococcus epidermidis</italic> could prevent sepsis in infants, but results showed no difference between placebo and experimental groups [<xref rid="B21-microorganisms-08-01936" ref-type="bibr">21</xref>]. A single chain variable fragment targeting Adenosine triphosphate(ATP)-binding cassette (ABC) transporter GrfA was shown as ineffective in phase II clinical trials in another study [<xref rid="B14-microorganisms-08-01936" ref-type="bibr">14</xref>]. The remaining five studies utilized monoclonal antibodies against <italic toggle="yes">S. aureus</italic> proteins. One study found that the administration of &#945;-ClfA antibodies did not offer significant protection [<xref rid="B22-microorganisms-08-01936" ref-type="bibr">22</xref>]. Similarly, monoclonal antibodies targeting Hla, PVL, LukED, and &#947;-hemolysin AB and CB (HlgAB, HlgCB) failed to protect against infection in mechanically-ventilated patients [<xref rid="B23-microorganisms-08-01936" ref-type="bibr">23</xref>]. A monoclonal antibody targeting lipoteichoic acid (LTA) did not significantly protect against sepsis in low birthweight infants [<xref rid="B24-microorganisms-08-01936" ref-type="bibr">24</xref>]. Another study tested a modified monoclonal antibody against Hla with an extended half-life to protect against <italic toggle="yes">S. aureus</italic> infection in mechanically ventilated patients. Unfortunately, treatment with this antibody also failed to confer protection to the treated group [<xref rid="B25-microorganisms-08-01936" ref-type="bibr">25</xref>]. A more recent trial (Aridis Pharmaceuticals) is testing if the transfer of monoclonal antibodies against <italic toggle="yes">S. aureus</italic> Hla can treat community-acquired bacterial pneumonia or ventilator-associated pneumonia in patients, but this is still an ongoing trial and the results are not known. Overall, so far, the clinical trials concur with observations from murine model studies (see below), which indicate that antibody responses alone are not sufficient to protect against <italic toggle="yes">S. aureus</italic> re-infection. Other arms of the adaptive response, such as T cells, play important roles in protecting against this bacterium and therefore need to be engaged by vaccination approaches.</p><p>The notion that T cell immunity needs to be harnessed in vaccine development is also supported by observations from recent active immunization trials (<xref rid="microorganisms-08-01936-t002" ref-type="table">Table 2</xref>), such as the failed V710 vaccine phase II/III clinical trial carried out by Merck in 2011. Vaccination with V710, an IsdB recombinant protein vaccine, generated abundant anti-IsdB antibodies however, the rate of <italic toggle="yes">S. aureus</italic> infection was comparable between placebo and vaccinated groups [<xref rid="B27-microorganisms-08-01936" ref-type="bibr">27</xref>]. Additionally, antibody titers in patients who developed <italic toggle="yes">S. aureus</italic> infection were similar to those who did not develop the disease [<xref rid="B28-microorganisms-08-01936" ref-type="bibr">28</xref>]. An analysis of cytokines associated with T cell function revealed that patients who developed fatal <italic toggle="yes">S. aureus</italic> infections had lower expression of IL-2 and IL-17A than those who survived the infection. In addition to the V710 trial, two other active staphylococcal vaccines that advanced to phase II/III clinical trials, StaphVax (Nabi) targeting CP5/CP8, and SA-4Ag (Pfizer, New York, NY, USA) targeting four staphylococcal antigens, also demonstrated a lack of efficacy in spite of robust antibody induction. Together, these observations support the importance of refocusing vaccine approaches to engage other arms of the immune system beyond the humoral response.</p></sec><sec id="sec3-microorganisms-08-01936"><title>3. Innate Immune Responses to <italic toggle="yes">S. aureus</italic></title><p>The innate immune responses to <italic toggle="yes">S. aureus</italic> and the pathogen&#8217;s strategies to counteract these responses have been the topic of many other recent and comprehensive reviews [<xref rid="B36-microorganisms-08-01936" ref-type="bibr">36</xref>,<xref rid="B37-microorganisms-08-01936" ref-type="bibr">37</xref>]. Here, we briefly summarize the innate response to <italic toggle="yes">S. aureus</italic> and focus mainly on the adaptive immune response as we discuss the new findings that can potentially inform the development of new vaccines. The innate immune system broadly recognizes invading pathogens through receptors that ligate pathogen-related molecular patterns (PAMPs), including single stranded RNA, lipopolysaccharide (LPS), and peptidoglycan (PGN). PAMPs are bound via pattern recognition receptors (PRRs), i.e., Toll-like receptors (TLRs), NOD-like receptors (NLRs), and/or C-type lectin receptors (CLRs). PRRs are mainly expressed by innate immune cells such as macrophages, monocytes, dendritic cells (DCs), and neutrophils. The sensing of PAMPs by TLRs initiates a signaling cascade that involves adaptor proteins myeloid differentiation primary response 88 (Myd88) or Toll/interleukin-1 receptor-domain-containing adapter-inducing interferon-&#946; (TRIF). This is followed by interleukin-1 receptor-associated kinases (IRAKs), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) or mitogen-activated protein kinase (MAPK) with a subsequent governance of pro-inflammatory gene expression. Alternatively, NF-kB activation by NOD2 signaling is modulated by receptor-interacting serine/threonine protein kinase 2 (RICK or RIP2).</p><p>The major <italic toggle="yes">S. aureus</italic>-associated PAMP sensed by the innate immune system appears to be LTA in addition to other lipoproteins, PGN, cell wall glycopolymers, RNA, and unmethylated CpG DNA. The recognition of <italic toggle="yes">S. aureus</italic>-LTA relies on the heterodimer, TLR2-TLR6, which senses diacylated lipoproteins such as LTA. Other receptors that recognize <italic toggle="yes">S. aureus</italic> PAMPs include NOD2, mannose-binding lectin, L-ficolin, surfactant protein A, TLR8, TLR9, and heterodimer TLR2-TLR1. The importance of TLR2, Myd88, IL-1 signaling, and NOD2 is underlined by several knockout mice studies. Knockout of TLR2, Myd88, IL-1R, or NOD2 increases the bacterial burden during infection compared to wild-type controls [<xref rid="B38-microorganisms-08-01936" ref-type="bibr">38</xref>,<xref rid="B39-microorganisms-08-01936" ref-type="bibr">39</xref>,<xref rid="B40-microorganisms-08-01936" ref-type="bibr">40</xref>]. The importance of TLR, Myd88, and IL-1R signaling is mirrored in humans. Patients with defects in TLR, Myd88, IRAK4, and IL-1R signaling have higher incidence of <italic toggle="yes">S. aureus</italic> infections [<xref rid="B41-microorganisms-08-01936" ref-type="bibr">41</xref>,<xref rid="B42-microorganisms-08-01936" ref-type="bibr">42</xref>,<xref rid="B43-microorganisms-08-01936" ref-type="bibr">43</xref>,<xref rid="B44-microorganisms-08-01936" ref-type="bibr">44</xref>].</p><p>The binding of LTA by TLR2-TLR6 occurs on macrophages/monocytes as well as DCs. This triggers the expression/release of pro-inflammatory cytokines, such as IL-1b, IL-8, IL-10, IL-12, TNF-&#945; and chemoattractants, MIP-1&#945;, MCP-1, granulocyte colony-stimulating factor (GM-CSF), leukotriene B4, and complement factor 5a [<xref rid="B45-microorganisms-08-01936" ref-type="bibr">45</xref>]. Chemoattractants recruit neutrophils to the site of infection, which clear the invading bacteria, while the pro-inflammatory cytokines act as chemoattractants as well as help shape the immune response [<xref rid="B45-microorganisms-08-01936" ref-type="bibr">45</xref>] (<xref ref-type="fig" rid="microorganisms-08-01936-f001">Figure 1</xref>). After encountering <italic toggle="yes">S. aureus</italic>, DCs and macrophages travel from the site of infection to the draining lymph node where they can present <italic toggle="yes">S. aureus</italic> antigens to T cells. At least one study showed that that deletion of DCs by <italic toggle="yes">S. aureus</italic> &#945;-toxin prevented the formation of a protective immune memory in a skin infection model [<xref rid="B46-microorganisms-08-01936" ref-type="bibr">46</xref>], suggesting that DC-mediated antigen presentation is crucial for the development of successful adaptive immune responses against <italic toggle="yes">S. aureus</italic> (see below). The production of cytokines, as well as expression of co-stimulatory molecules by DCs help to initiate and direct the functional differentiation of T cell subsets that will ultimately shape the adaptive response to the infection.</p><p>In addition to DCs and macrophages, neutrophils have also been shown to play crucial roles in the immune response against <italic toggle="yes">S. aureus</italic>. Patients with neutropenia or defects in neutrophil function have higher incidences of <italic toggle="yes">S. aureus</italic> infections [<xref rid="B47-microorganisms-08-01936" ref-type="bibr">47</xref>,<xref rid="B48-microorganisms-08-01936" ref-type="bibr">48</xref>,<xref rid="B49-microorganisms-08-01936" ref-type="bibr">49</xref>,<xref rid="B50-microorganisms-08-01936" ref-type="bibr">50</xref>]. In animal models, it has been demonstrated that the recruitment of neutrophils leads to a decrease in bacterial burden, thus identifying neutrophils as a main player in clearing bacteria during infection. Neutrophils kill bacteria in several ways, such as via the creation of reactive oxygen species (ROS), production of antimicrobial peptides (AMPs), release of neutrophil extracellular traps (NETs), and degradation of bacteria through proteinases and hydrolases [<xref rid="B51-microorganisms-08-01936" ref-type="bibr">51</xref>,<xref rid="B52-microorganisms-08-01936" ref-type="bibr">52</xref>,<xref rid="B53-microorganisms-08-01936" ref-type="bibr">53</xref>]. As we discuss below, although the innate immune response to <italic toggle="yes">S. aureus</italic> is important for controlling bacterial burden during infection, innate signaling upon natural infection appears inadequate to instruct the development of fully protective adaptive T and B cell responses against the bacteria. Work from our group has shown that manipulation of peptidoglycan O-acetylation leads to cell-wall resistance to lysozyme degradation thus shielding many staphylococcal cell-wall associated PAMPs from host detection. This results in the impaired production of various pro-inflammatory cytokines including IL-1b, IL-6, IL-23, and suboptimal development of protective Th1 and Th17 responses [<xref rid="B54-microorganisms-08-01936" ref-type="bibr">54</xref>].</p></sec><sec id="sec4-microorganisms-08-01936"><title>4. Adaptive Immune Response to <italic toggle="yes">S. aureus</italic></title><sec id="sec4dot1-microorganisms-08-01936"><title>4.1. B Cell Responses</title><p>Infection or colonization with <italic toggle="yes">S. aureus</italic> leads to the production of antibodies against both surface-bound proteins [<xref rid="B55-microorganisms-08-01936" ref-type="bibr">55</xref>] and staphylococcal toxins [<xref rid="B56-microorganisms-08-01936" ref-type="bibr">56</xref>,<xref rid="B57-microorganisms-08-01936" ref-type="bibr">57</xref>]. These anti-staphylococcal antibodies are of various subclasses, i.e., IgM, IgA, and IgG. However, similarly to other successful pathogens, <italic toggle="yes">S. aureus</italic> has acquired strategies to evade host antibody responses. Two staphylococcal toxins, Surface Protein A (SpA) and second immunoglobulin binding protein (Sbi) can bind the Fc region of antibodies, which can prevent opsonization-mediated phagocytosis [<xref rid="B58-microorganisms-08-01936" ref-type="bibr">58</xref>]. Additionally, both proteins interfere with complement activation to prevent opsonization [<xref rid="B58-microorganisms-08-01936" ref-type="bibr">58</xref>]. SpA can act also as a B cell superantigen by binding the F(ab)2 portion of the B cell receptor, which leads to the inhibition of antibody production by inducing cell death [<xref rid="B59-microorganisms-08-01936" ref-type="bibr">59</xref>].</p><p>A few studies have noted that antibody titers against <italic toggle="yes">S. aureus</italic> toxins correlate with better disease outcome. One study showed that the risk of sepsis was lower in individuals who had higher levels of IgG against &#945;-hemolysin (Hla), &#948;-hemolysin (Hld), Panton Valentine leukocidin (PVL), staphylococcal enterotoxin C-1 (SEC-1), and phenol-soluble modulin &#945;3 (PSM-&#945;3) [<xref rid="B60-microorganisms-08-01936" ref-type="bibr">60</xref>]. Another study looked at acute and convalescent antibodies levels in individuals with different types of infections, including first time skin and soft-tissue (SSTI), recurrent SSTI, and invasive infections, such as bacteremia, osteomyelitis, septic arthritis, bursitis, pyomyositis, empyema, endocarditis, or septic thrombophlebitis [<xref rid="B61-microorganisms-08-01936" ref-type="bibr">61</xref>]. The patient group that had the highest convalescent titers was the invasive infection cohort. This group had an increase in production of &#945;-Hla antibody titers, which correlated with protection against subsequent infection within 12 months. In contrast, SSTI did not induce long-lasting antibody production. These observations suggest that the route of infection can affect the type of humoral immune response mounted against <italic toggle="yes">S. aureus</italic>. Additionally, our recent study showed that the adoptive transfer of sera from children with invasive staphylococcal diseases protected na&#239;ve mice from systemic staphylococcal infection [<xref rid="B62-microorganisms-08-01936" ref-type="bibr">62</xref>]. However, protection conferred by the sera was only observed with some of the convalescent serum samples and sera collected at 6 months post-infection were not protective, albeit the size of the study was small. These antibodies most likely neutralized <italic toggle="yes">S. aureus</italic> toxins, which in addition to preventing damage caused by the toxin also prevented progression of infection. Another study in mice found that serum transfer after vaccination against ClfA, ClfB, Hla, IsdA, IsdB, and SdrD prevented bacteremia and reduced dermonecrosis but did not reduce the bacterial burden in abscesses or GI colonization [<xref rid="B63-microorganisms-08-01936" ref-type="bibr">63</xref>].</p><p>Although the studies discussed above indicate that B cells are capable of eliciting anti-staphylococcal responses, one of our most recent studies showed that antibodies were dispensable for protective immunity against <italic toggle="yes">S. aureus</italic> in mice vaccinated with four different <italic toggle="yes">S. aureus</italic> recombinant proteins (ClfA, IsdA, MntC, and SdrE) encapsulated in &#946;-glucan particles [<xref rid="B64-microorganisms-08-01936" ref-type="bibr">64</xref>]. Importantly, B cell-deficient mice and patients with X-linked agammaglobulinemia, a genetic disorder that results in severe B cell deficiency, do not have increased susceptibility to <italic toggle="yes">S. aureus</italic> infection [<xref rid="B65-microorganisms-08-01936" ref-type="bibr">65</xref>,<xref rid="B66-microorganisms-08-01936" ref-type="bibr">66</xref>]. Despite these observations, the majority of vaccine studies, including several clinical trials (<xref rid="microorganisms-08-01936-t002" ref-type="table">Table 2</xref>) have focused on antibody production as a measure of induction of protective immunity. As we discuss below, there is strong evidence that T cell-mediated immunity is required for long-lasting protection against <italic toggle="yes">S. aureus</italic> infection. Thus, the data so far support the notion that the engagement of certain T helper cell subsets, which are usually suppressed by natural infection, is a key component for the development of protective immunity to re-infection, and therefore should be the basis of novel approaches for vaccine development.</p></sec><sec id="sec4dot2-microorganisms-08-01936"><title>4.2. T Cell Responses</title><p>T cells make up the other branch of the adaptive immune response and are defined by the expression of the T cell receptor (TCR) which can either be comprised of gamma and delta chains (&#947;&#948;TCR) or alpha and beta chains (&#945;&#946;TCR). One difference between these cell subsets is that &#947;&#948;-T cells do not have a broad clonal diversity as &#945;&#946;-T cells, and thus epitope coverage by &#945;&#946;-T cells is wider compared to &#947;&#948;-T cells.</p><sec id="sec4dot2dot1-microorganisms-08-01936"><title>4.2.1. Roles of &#947;&#948; T Cells</title><p>Several studies have indicated that &#947;&#948;-T cells play important roles in the control of <italic toggle="yes">S. aureus</italic> infection. One study described more severe skin pathology in &#947;&#948;-T cell knockout mice, which was attributed to decreased IL-17 production [<xref rid="B67-microorganisms-08-01936" ref-type="bibr">67</xref>]. Another study reported the expansion of certain &#947;&#948;-T cell clones after infection. Furthermore, the adoptive transfer of &#947;&#948;-T cells from mice previously infected with <italic toggle="yes">S. aureus</italic> protected na&#239;ve mice from infection, suggesting that &#947;&#948;-T cells could provide some sort of protective memory to <italic toggle="yes">S. aureus</italic> infection [<xref rid="B68-microorganisms-08-01936" ref-type="bibr">68</xref>]. However, in that study, the &#947;&#948;-T cells were primed in the absence of IL-1&#946;, which differs from what happens during natural <italic toggle="yes">S. aureus</italic> infection. Moreover, as measured by lesion size and bacterial burden, protection induced by the adoptively transferred &#947;&#948;-T cells was modest and only apparent during early time points after infection. Nonetheless, there is precedence for a role of &#8220;memory&#8221; &#947;&#948;-T cells in other bacterial infection models. For example, &#8220;memory&#8221; Vg4<sup>+</sup> &#947;&#948;-T cells have been shown to provide IL-17-dependent protection against <italic toggle="yes">Listeria monocytogenes</italic> oral infection [<xref rid="B69-microorganisms-08-01936" ref-type="bibr">69</xref>]. Thus, it is conceivable that &#947;&#948;-T cells could contribute to memory responses to <italic toggle="yes">S. aureus</italic> infection in specific circumstances, but this remains to be validated.</p></sec><sec id="sec4dot2dot2-microorganisms-08-01936"><title>4.2.2. Roles of &#945;&#946; T Cells</title><p>&#945;&#946;-T cells make up the majority of T cells and their functions can be defined on the basis of their expression of the surface molecules CD4 and CD8. CD4<sup>+</sup> T cells, also called helper T (Th) cells, contribute to immune responses against infections by providing help to B cells and CD8<sup>+</sup> T cells. In contrast, CD8<sup>+</sup> T cells, also called cytotoxic T cells, lyse cells that are infected by pathogens. CD4<sup>+</sup> T cells have critical roles in the defense against extracellular pathogens, whereas CD8<sup>+</sup> T cells preferentially recognize and kill intracellular/viral pathogens and tumor cells. CD4<sup>+</sup> helper T cells can differentiate into different subsets, including Th1, Th2, and Th17, among others [<xref rid="B70-microorganisms-08-01936" ref-type="bibr">70</xref>]. These Th subsets are mainly defined by the cytokines they produce and their role in certain immune responses. Th1 cells depend on the transcription factor, T-bet, for differentiation. They preferentially produce IL-2 and IFN&#947; and have been shown to help protect against intracellular pathogens [<xref rid="B70-microorganisms-08-01936" ref-type="bibr">70</xref>]. The development of Th2 cells requires the transcription factor GATA-3, which is important to mediate the expression of the majority of Th2-associated cytokines, including IL-4, IL-5, and IL-13 [<xref rid="B70-microorganisms-08-01936" ref-type="bibr">70</xref>]. Th2 cells are associated with humoral immunity and parasitic infections. Th17 cells require the expression of ROR&#947;t and several other transcription factors [<xref rid="B70-microorganisms-08-01936" ref-type="bibr">70</xref>] and produce primarily IL-17 family cytokines (IL-17A, F, C, and E) in addition to IL-22 and, in some cases, GM-CSF. Th17 cells have been shown to mediate protection against extracellular pathogens such as bacteria and fungi [<xref rid="B70-microorganisms-08-01936" ref-type="bibr">70</xref>]. In addition, Th cells can also originate T follicular helper cells (T<sub>FH</sub>), which require the transcription factor BCL-6. T<sub>FH</sub> produce cytokines, such as IL-21, which promote B cell responses [<xref rid="B70-microorganisms-08-01936" ref-type="bibr">70</xref>]. The differentiation of Th cells can also result in the generation of Foxp3<sup>+</sup> regulatory T cells (termed inducible T<sub>REG</sub> cells), which have similar functions as thymic derived (t) T<sub>REG</sub> [<xref rid="B70-microorganisms-08-01936" ref-type="bibr">70</xref>].</p><p>Evidence to date suggests that both CD4<sup>+</sup> and CD8<sup>+</sup> T cells are important for immunity against <italic toggle="yes">S. aureus</italic> infection. Investigations have focused on CD4<sup>+</sup> T cells because <italic toggle="yes">S. aureus</italic> is traditionally considered an extracellular pathogen. However, there is data indicating that once internalized by cells such as macrophages, <italic toggle="yes">S. aureus</italic> escapes phagosomes to enter the cytoplasm, and therefore becomes an intracellular pathogen [<xref rid="B71-microorganisms-08-01936" ref-type="bibr">71</xref>] that requires control by CD8<sup>+</sup> T cells or NK cells. In contrast, studies in murine models indicate that CD8<sup>+</sup> &#945;&#946;-T cells are dispensable during <italic toggle="yes">S. aureus</italic> infection [<xref rid="B72-microorganisms-08-01936" ref-type="bibr">72</xref>,<xref rid="B73-microorganisms-08-01936" ref-type="bibr">73</xref>], whereas there is an abundance of data, in empyema and skin infection models, supporting a central role of CD4<sup>+</sup> T cells. Of note, <italic toggle="yes">S. aureus</italic> has developed several virulence factors to counteract CD4<sup>+</sup> &#945;&#946;-T cell responses including the superantigens staphylococcal enterotoxin A (SEA), enterotoxin B (SEB), and toxic shock syndrome toxin (TSST-1), which bind major histocompatibility complexes (MHC) II and T cell receptors (TCR). This binding of MHC class II and TCR activates the uncontrolled release of inflammatory cytokines from T cells, followed by the induction of T cell anergy or deletion. Additional staphylococcal strategies consist of the expression of an MHC class II analog protein (Map), which binds directly to TCR to attenuate T cell responses [<xref rid="B74-microorganisms-08-01936" ref-type="bibr">74</xref>], and the expression of the LukED toxin that lyses T cells following ligation to the CCR5 receptor [<xref rid="B75-microorganisms-08-01936" ref-type="bibr">75</xref>]. The importance of CD4<sup>+</sup> T cells in the immune response against <italic toggle="yes">S. aureus</italic> in humans is supported by the observation that HIV patients with decreased CD4<sup>+</sup> T cells have increased prevalence of <italic toggle="yes">S. aureus</italic> infections [<xref rid="B76-microorganisms-08-01936" ref-type="bibr">76</xref>,<xref rid="B77-microorganisms-08-01936" ref-type="bibr">77</xref>,<xref rid="B78-microorganisms-08-01936" ref-type="bibr">78</xref>].</p><p>Studies of the mechanisms underlying CD4<sup>+</sup> T cells roles in <italic toggle="yes">S. aureus</italic> infection indicate that IFN&#947; may be dispensable during primary infection, whereas the requirement for IL-17 varies depending on the infection model. One study found that IFN&#947; knockout mice had higher survival rates and lower bacterial burdens during intravenous infection compared to wild type controls [<xref rid="B79-microorganisms-08-01936" ref-type="bibr">79</xref>]. Similarly, another study found that there was no effect on primary skin <italic toggle="yes">S. aureus</italic> infection in IFN&#947;-receptor knockout mice, suggesting that IFN&#947; signaling is not required for bacterial clearance in the skin [<xref rid="B67-microorganisms-08-01936" ref-type="bibr">67</xref>]. In contrast, primary cutaneous infection in IL-17-receptor knockout mice resulted in larger lesions and bigger bacterial burdens compared to wild type mice, whereas IL-17-deficient mice had mortality rates comparable to that observed in wild type mice during intravenous infection [<xref rid="B80-microorganisms-08-01936" ref-type="bibr">80</xref>,<xref rid="B81-microorganisms-08-01936" ref-type="bibr">81</xref>]. Thus, during primary <italic toggle="yes">S. aureus</italic> infection, IFN&#947; seems to be dispensable while IL-17 is only conditionally required.</p><p>In contrast to the observed in primary infection, it is well established that both Th1 and Th17 CD4<sup>+</sup> T cells are required to mediate protection against <italic toggle="yes">S. aureus</italic> in different models of re-infection in mice. One study found that the transfer of IFN&#947; producing &#945;&#946;-CD4<sup>+</sup> T cells protected against <italic toggle="yes">S. aureus</italic> peritoneal infection by a mechanism that involved the activation of peritoneal macrophages [<xref rid="B82-microorganisms-08-01936" ref-type="bibr">82</xref>]. Likewise, protection against <italic toggle="yes">S. aureus</italic> peritoneal infection was conferred by an IL-17-dependent mechanism in another vaccination study [<xref rid="B83-microorganisms-08-01936" ref-type="bibr">83</xref>]. Lin et al. also showed that vaccination with recombinant N-terminus of the <italic toggle="yes">Candida albicans</italic> adhesin protein Als3p, which is structurally similar to <italic toggle="yes">S. aureus</italic> ClfA, induced IFN&#947; and IL-17A single- and double-producing CD4<sup>+</sup> T cells that protected against <italic toggle="yes">S. aureus</italic> bloodstream infection. In this model, protection was associated with increased neutrophil influx, which reduced bacterial burden [<xref rid="B84-microorganisms-08-01936" ref-type="bibr">84</xref>].</p><p>In a different study, vaccination with a multiple antigen presenting system with six staphylococcal proteins led to the differentiation of CD4<sup>+</sup> T cells that produced both IFN&#947; and IL-17A, which mediated protection against both bloodstream and skin infections [<xref rid="B63-microorganisms-08-01936" ref-type="bibr">63</xref>]. Additionally, in a study showing that immunization intravenously could protect mice against subcutaneous infection, this protection was mediated by CD4<sup>+</sup> T cells and was associated with an increase in IFN&#947; production [<xref rid="B46-microorganisms-08-01936" ref-type="bibr">46</xref>]. In one of our recent studies, we found that the vaccination of mice with &#946;-glucan particles loaded with four different proteins from <italic toggle="yes">S. aureus</italic> also generated an innate immune response that fostered the development of Th1 and Th17 cells that could transfer protection to na&#239;ve mice [<xref rid="B64-microorganisms-08-01936" ref-type="bibr">64</xref>].</p><p>Although the requirement for IL-17 in the immune response to <italic toggle="yes">S. aureus</italic> is clearly illustrated by the studies mentioned above, the cellular source of this cytokine during <italic toggle="yes">S. aureus</italic> infection is less clear with conflicting reports showing a role for both &#945;&#946; and &#947;&#948; T cells. Cho et al. suggested that IL-17 was produced by &#947;&#948;-T cells, which recruited neutrophils for the control of <italic toggle="yes">S. aureus</italic> primary skin infection [<xref rid="B67-microorganisms-08-01936" ref-type="bibr">67</xref>]. In contrast, Montgomery et al. found that IL-17A and CD4<sup>+</sup> T cells were the key to controlling <italic toggle="yes">S. aureus</italic> infection in the skin [<xref rid="B73-microorganisms-08-01936" ref-type="bibr">73</xref>]. Additionally, Marchitto et al. showed that upon skin infection, both CD4<sup>+</sup> and &#947;&#948;-T cells produced IL-17A/F at the site of infection as well as in the draining lymph node [<xref rid="B68-microorganisms-08-01936" ref-type="bibr">68</xref>]. However, they concluded that the expression of IL-17A was higher in &#947;&#948;-T cells. Thus, both &#945;&#946;-CD4<sup>+</sup> T cells as well as &#947;&#948;-T cells can produce IL-17 and be required to control <italic toggle="yes">S. aureus</italic> infection. The importance of IFN&#947; and IL-17 in the response to <italic toggle="yes">S. aureus</italic> infection in humans is supported by several studies [<xref rid="B79-microorganisms-08-01936" ref-type="bibr">79</xref>,<xref rid="B80-microorganisms-08-01936" ref-type="bibr">80</xref>,<xref rid="B81-microorganisms-08-01936" ref-type="bibr">81</xref>,<xref rid="B85-microorganisms-08-01936" ref-type="bibr">85</xref>]. The role of IL-17 is further indicated by the finding that individuals with genetic defects that interfere with the differentiation of Th17 cells, such as STAT3 loss-of-function mutations or hyper-IgE syndrome, have a higher incidence of <italic toggle="yes">S. aureus</italic> infection [<xref rid="B86-microorganisms-08-01936" ref-type="bibr">86</xref>,<xref rid="B87-microorganisms-08-01936" ref-type="bibr">87</xref>,<xref rid="B88-microorganisms-08-01936" ref-type="bibr">88</xref>].</p><p>In addition to <italic toggle="yes">S. aureus</italic>, Th17 cells and IL-17 are crucial in the response to several other extracellular bacterial infections. Likewise, Th1 cells and IFN&#947; play important roles in the response to many intracellular pathogens. Although advantageous in the context of these infections, both IL-17 and IFN&#947; are highly inflammatory cytokines and can cause unwanted harm to host tissues. Consequently, Th1 and Th17 responses must be tightly regulated. The immune system has evolved to deploy several different mechanisms to control Th1 and Th17 responses. One important mechanism used to control IL-17 and IFN&#947; actions is the expression of the regulatory cytokines TGF&#946; and IL-10, which can be produced by many different immune cell types. The role of TGF&#946; in the immune response to <italic toggle="yes">S. aureus</italic> has not been extensively evaluated, but at least one study showed that culture of bovine mammary epithelial cells with heat-killed <italic toggle="yes">S. aureus</italic> leads to the expression of TGF&#946; [<xref rid="B89-microorganisms-08-01936" ref-type="bibr">89</xref>]. Another study showed that partial genetic deletion of TGF&#946; Receptor 2 (Tgfbr2) or the administration of a TGF&#946; receptor inhibitor in mice was associated with improved bacterial clearance in the skin [<xref rid="B90-microorganisms-08-01936" ref-type="bibr">90</xref>]. These data suggest that <italic toggle="yes">S. aureus</italic>-induced TGF&#946; could play a role in damping the responses against the infection in the skin, but this remains to be further studied.</p><p>The role of IL-10 in the immune response to <italic toggle="yes">S. aureus</italic> infection is not fully understood. In studies looking at systemic infection, IL-10 appears to be protective; IL-10 deficient mice had higher bacterial burdens compared to wild type controls [<xref rid="B91-microorganisms-08-01936" ref-type="bibr">91</xref>,<xref rid="B92-microorganisms-08-01936" ref-type="bibr">92</xref>]. Additionally, one study found that the incidence of <italic toggle="yes">S. aureus</italic>-induced arthritis was higher in IL-10-deficient mice [<xref rid="B92-microorganisms-08-01936" ref-type="bibr">92</xref>]. In contrast, during skin infection, IL-10-deficient mice had smaller lesion sizes and lower bacterial burdens compared to wild type counterparts [<xref rid="B91-microorganisms-08-01936" ref-type="bibr">91</xref>]. These data suggest the complex role of IL-10 during <italic toggle="yes">S. aureus</italic> infection may depend on the route of infection.</p><p>Importantly, when na&#239;ve human T cells were cultured with <italic toggle="yes">S. aureus</italic>, they produced IL-10 in addition to IL-17 [<xref rid="B93-microorganisms-08-01936" ref-type="bibr">93</xref>]. However, if the T cells were cultured with <italic toggle="yes">S. aureus</italic> along with IL-1&#946;, the cells secreted IL-17 and IFN&#947;, but not IL-10. This was in stark contrast to what was observed with <italic toggle="yes">C. albicans</italic>, which caused human T cells to produce IL-17 and IFN&#947; and very little IL-10 without any manipulation to the culture conditions. An additional study in human samples observed that higher IL-10 serum levels correlate with higher rates of mortality in patients with bacteremia caused by <italic toggle="yes">S. aureus</italic> [<xref rid="B94-microorganisms-08-01936" ref-type="bibr">94</xref>], suggesting that it can play an inhibitory role in human immunity. Together, these observations suggest that <italic toggle="yes">S. aureus</italic> can somehow manipulate the immune response to prevent the differentiation of IL-17 and potentially IFN&#947;-producing cells and/or undermine the actions of these cells. In line with that, our recent study showed that O-acetylation of peptidoglycan by <italic toggle="yes">S. aureus</italic> leads to a preferential expression of IL-10 instead of IL-17 or IFN&#947;. Furthermore, deletion of O-acetyl transferase in <italic toggle="yes">S. aureus</italic> increased the expression of cytokines associated with Th17 polarization and contributes to protection from intraperitoneal reinfection via an IL-17-dependent mechanism [<xref rid="B54-microorganisms-08-01936" ref-type="bibr">54</xref>]. We also found that immunized IL-10-deficient mice had improved bacterial clearance upon intraperitoneal infection with <italic toggle="yes">S. aureus</italic>, and importantly, protection induced by genetic deficiency of IL-10 could be transferred to na&#239;ve mice by the adoptive transfer of CD4<sup>+</sup> T cells. Thus, the expression of IL-10 by CD4<sup>+</sup> T cells upon primary infection with <italic toggle="yes">S. aureus</italic> is likely one of the factors contributing to the lack of robust long-lasting protective CD4<sup>+</sup> T cell memory responses.</p><p>The cellular source of IL-10 and the exact mechanisms by which IL-10 shapes effector and potentially memory CD4<sup>+</sup> T cells responses to <italic toggle="yes">S. aureus</italic> infection remain to be elucidated. Considering the evidence above, it is tempting to speculate that the use of adjuvants that could counteract the induction of IL-10 by <italic toggle="yes">S. aureus</italic> could be a promising approach for the development of new vaccines to favor the induction of robust Th17 and Th1 responses and potentially generate long-lasting protective immunity against <italic toggle="yes">S. aureus</italic>.</p></sec><sec id="sec4dot2dot3-microorganisms-08-01936"><title>4.2.3. Tissue Resident Memory T Cells</title><p>Tissue-resident memory T cells (T<sub>RM</sub>) are a recently described memory T cell subset that is thought to reside in tissues long-term. Similar to other T cell memory subsets, T<sub>RM</sub> respond rapidly and specifically upon re-infection [<xref rid="B95-microorganisms-08-01936" ref-type="bibr">95</xref>], but have the added advantage to be present at the site of injury and therefore could provide a fast and efficient response against insults. The exact mechanisms underlying the differentiation of T<sub>RM</sub> are not fully understood. Studies using different infection models [<xref rid="B95-microorganisms-08-01936" ref-type="bibr">95</xref>,<xref rid="B96-microorganisms-08-01936" ref-type="bibr">96</xref>,<xref rid="B97-microorganisms-08-01936" ref-type="bibr">97</xref>], indicate that T<sub>RM</sub> cells develop from memory precursors that enter the tissue during the effector phase of infection and remain in the tissue afterwards [<xref rid="B98-microorganisms-08-01936" ref-type="bibr">98</xref>]. However, the exact regulation of this process is unknown.</p><p>One mechanism by which tissue retention of T<sub>RM</sub> is thought to occur is through the antagonism of sphingosine 1-phosphate receptor-1 (S1PR1) by the surface molecule CD69, also called early T cell-activation antigen P60 [<xref rid="B99-microorganisms-08-01936" ref-type="bibr">99</xref>]. S1PR1 regulates the egress of T cells from tissues and CD69 likely binds S1PR1 directly, causing a conformational change that interferes with its function [<xref rid="B100-microorganisms-08-01936" ref-type="bibr">100</xref>]. Of note, the expression of S1PR1 along with other genes involved in secondary lymphoid organ (SLO) recirculation are regulated by the transcription factor Krupple-like factor 2 (KLF2), which is downregulated in T<sub>RM</sub> cells [<xref rid="B101-microorganisms-08-01936" ref-type="bibr">101</xref>]. Additionally, if the expression of S1PR1 is induced outside of its typical regulation, it reduces the frequency of cells localizing to non-lymphoid tissues. CD103 (integrin &#945;E) and CD49a (integrin &#945;1) are other surface markers associated with the T<sub>RM</sub> phenotype that might aid in the retention of these cells in the tissues. CD103 binds E-cadherin with integrin beta 7 and is thought to enable the cells to enter and remain in the tissue. CD49a binds collagen along with CD29 (integrin beta 1) to help retain cells in collagen-rich tissues [<xref rid="B102-microorganisms-08-01936" ref-type="bibr">102</xref>]. Additionally, T<sub>RM</sub> lack the expression of the chemokine receptors CCR7 and CD62L, which are required for homing to lymph nodes.</p><p>Several studies have detailed the importance of T<sub>RM</sub> during re-infection at specific sites such as, the lungs, skin, and female reproductive tract. Our current knowledge of T<sub>RM</sub> biology is largely based on studies focusing on CD8<sup>+</sup> T<sub>RM</sub> cells residing in the tissue long-term, with many fewer studies detailing the characteristics of CD4<sup>+</sup> T<sub>RM</sub>. Therefore, the bulk of the data discussed below is based on CD8<sup>+</sup> studies. Similarities and differences with CD4<sup>+</sup> T<sub>RM</sub> are highlighted/discussed when appropriate.</p><p>As alluded to above, the mechanisms underlying T<sub>RM</sub> cell differentiation and function are poorly defined. In addition to KLF2, mentioned above, there are several other transcription factors that may play a role in the establishment of T<sub>RM</sub> tissue residency, including Blimp-1, Hobit, T-bet, Eomes, and Runx3. Mackay et al. found that when the transcription factors Hobit and Blimp-1 were knocked out, significantly fewer T<sub>RM</sub> cells were found in the skin, gut, liver, and kidney in herpes simplex virus (HSV) and lymphocytic choriomeningitis virus (LCMV) experimental infection models [<xref rid="B103-microorganisms-08-01936" ref-type="bibr">103</xref>]. This study indicated that Blimp-1 and Hobit work together to modify transcriptional profiles that are required for T<sub>RM</sub> differentiation and potentially, for function. Similarly, deletion of the transcription factor Runx3 prevented the formation of T<sub>RM</sub> cells, especially CD69<sup>+</sup> CD103<sup>+</sup> T<sub>RM</sub> cells localized to the gut after LCMV infection [<xref rid="B104-microorganisms-08-01936" ref-type="bibr">104</xref>]. This study concluded that Runx3 was a transcriptional regulator that upregulated core genes responsible for tissue residency and downregulated genes important for circulating properties. Additionally, the downregulation of two other transcription factors, T-bet and Eomes, caused by TGF-&#946; signaling, was seen in T<sub>RM</sub> cells migrating to the skin after HSV infection [<xref rid="B105-microorganisms-08-01936" ref-type="bibr">105</xref>]. However, a complete ablation of T-bet resulted in the loss of these cells over time. This was likely because of the low expression of the IL-15 Receptor (IL15R) &#946; chain in these cells. IL-15 signaling is necessary for the long-term survival of T<sub>RM</sub> cells in the skin.</p><p>How cytokine signaling determines the fate of tissue-resident memory T cells is not well understood however, several studies have suggested that TGF&#946; plays a role in programming T cells to home to and reside in peripheral tissues. TGF&#946; stimulation of activated CD8<sup>+</sup> T cells in vitro causes a gene regulation signature that closely resembles that seen in T<sub>RM</sub>, which suggests that the T<sub>RM</sub> genetic signature could be regulated in part by TGF&#946; signaling [<xref rid="B106-microorganisms-08-01936" ref-type="bibr">106</xref>]. One study demonstrated that TGF&#946; released from DCs in the lymph nodes before infection predisposed CD8<sup>+</sup> T cells to home to the tissues after antigen stimulation [<xref rid="B107-microorganisms-08-01936" ref-type="bibr">107</xref>]. Similarly, Thompson et al. found that TGF&#946; released by monocytes caused the upregulation of CD103 on na&#239;ve T cells, which helped the T cells to migrate to peripheral tissues, such as the lung [<xref rid="B108-microorganisms-08-01936" ref-type="bibr">108</xref>]. Additionally, TGF&#946; was required for maintaining T<sub>RM</sub> within the intestines, which was linked to the induction of CD69 [<xref rid="B109-microorganisms-08-01936" ref-type="bibr">109</xref>].</p><p>Although the vast majority of T<sub>RM</sub> studies in murine models focus on CD8<sup>+</sup> T cells, at least three different studies indicate that CD4<sup>+</sup> T<sub>RM</sub> cells are important for protection against bacterial infection. Wilk et al. showed that CD4<sup>+</sup> T<sub>RM</sub> (CD44<sup>hi</sup> CD62L<sup>lo</sup> CD69<sup>+</sup> CD103<sup>+/&#8722;</sup>) cells could be found in the lungs of mice after <italic toggle="yes">Bordetella pertussis</italic> infection and that these cells conferred protection against re-infection [<xref rid="B110-microorganisms-08-01936" ref-type="bibr">110</xref>]. Another group demonstrated that CD4<sup>+</sup> T<sub>RM</sub> found in the lungs can protect against <italic toggle="yes">Klebsiella pneumoniae</italic> infection without the help of circulating CD4<sup>+</sup> T cells [<xref rid="B111-microorganisms-08-01936" ref-type="bibr">111</xref>]. Importantly, a 2015 study by Stary et al. found that vaccination-induced protection against <italic toggle="yes">Chlamydia trachomatis</italic> infection was mediated at least in part by CD4<sup>+</sup> T<sub>RM</sub> cells induced in the female reproductive tract of mice [<xref rid="B112-microorganisms-08-01936" ref-type="bibr">112</xref>]. This result suggests that vaccines can be designed to manipulate the immune response to optimize the induction of T<sub>RM</sub> cells that can protect against bacterial infection.</p><p>T<sub>RM</sub> surface markers identified in humans correspond with surface markers found in murine T<sub>RM</sub>, including CD69, CD103, and CD49a [<xref rid="B113-microorganisms-08-01936" ref-type="bibr">113</xref>]. However, a direct examination of the function of these cells in patients has not been performed and thus, the requirement of T<sub>RM</sub> for protection against bacterial infection in humans remains to be established. Nonetheless, at least a few studies indicate that in humans, both CD8<sup>+</sup> and CD4<sup>+</sup> T<sub>RM</sub> are required for vaccine-induced protection against viruses. Studies performed in human tissues, including the lung and skin, identified the presence of CD4<sup>+</sup> and CD8<sup>+</sup> T cells with specificity to ubiquitous human pathogens such as influenza [<xref rid="B114-microorganisms-08-01936" ref-type="bibr">114</xref>,<xref rid="B115-microorganisms-08-01936" ref-type="bibr">115</xref>], herpes simplex virus (HSV) [<xref rid="B116-microorganisms-08-01936" ref-type="bibr">116</xref>], cytomegalovirus (CMV) [<xref rid="B117-microorganisms-08-01936" ref-type="bibr">117</xref>], and respiratory syncytial virus (RSV) [<xref rid="B118-microorganisms-08-01936" ref-type="bibr">118</xref>]. Additionally, one study looking at RSV-specific T<sub>RM</sub> cells correlated an increase in T<sub>RM</sub> cells with lower viral titers [<xref rid="B118-microorganisms-08-01936" ref-type="bibr">118</xref>], suggesting that T<sub>RM</sub> cells help mediate the immune response upon re-infection, thereby providing protection.</p><p>The induction and functional requirement of T<sub>RM</sub> for long-term protective immunity against <italic toggle="yes">S. aureus</italic> remains to be investigated. However, if the generation of T<sub>RM</sub> cells upon primary infection with other bacteria is a requirement for protective immunity, as suggested by the data discussed above, then one could speculate that primary responses to <italic toggle="yes">S. aureus</italic> infection might not result in T<sub>RM</sub> cell generation (<xref ref-type="fig" rid="microorganisms-08-01936-f002">Figure 2</xref>). The generation of skin-specific T<sub>RM</sub> cells has been observed in several other infectious models, including <italic toggle="yes">Leishmania major</italic> [<xref rid="B119-microorganisms-08-01936" ref-type="bibr">119</xref>], vaccinia virus (VACV) [<xref rid="B120-microorganisms-08-01936" ref-type="bibr">120</xref>], LCMV [<xref rid="B121-microorganisms-08-01936" ref-type="bibr">121</xref>], and HSV [<xref rid="B122-microorganisms-08-01936" ref-type="bibr">122</xref>]. In these studies, T<sub>RM</sub> were shown to provide protection against re-infection. Furthermore, Linehan et al. found that <italic toggle="yes">S. epidermidis</italic>-specific CD8<sup>+</sup> T<sub>RM</sub> cells were created after an application of a strain from a particular clade (NIHLM087 from the A20 clade) [<xref rid="B123-microorganisms-08-01936" ref-type="bibr">123</xref>]. This study is of particular interest because <italic toggle="yes">S. epidermidis</italic> is closely related to <italic toggle="yes">S. aureus</italic> however, <italic toggle="yes">S. epidermidis</italic> is exclusively part of the microbiome, whereas <italic toggle="yes">S. aureus</italic> can cause pathogenic infections. Therefore, it is unlikely that the same vaccination strategy would work to induce the development of anti-<italic toggle="yes">S. aureus</italic> specific protective T<sub>RM</sub> cells, but that remains to be tested. Nonetheless, the fact that protective T<sub>RM</sub> responses can be generated against <italic toggle="yes">S. epidermidis</italic> is encouraging and might help to inform the criteria for the development of novel vaccination approaches against <italic toggle="yes">S. aureus</italic>. Future studies should focus on what aids in creating <italic toggle="yes">S. aureus</italic>-specific T<sub>RM</sub> cells and the possible hurdles that need to be overcome to create <italic toggle="yes">S. aureus</italic>-specific T<sub>RM</sub> cells.</p></sec></sec></sec><sec id="sec5-microorganisms-08-01936"><title>5. Concluding Remarks and Future Directions</title><p>Despite promising pre-clinical studies, every anti-staphylococcal vaccine developed to date has failed in clinical trials. It is still unclear why these experimental vaccines have not translated into successful vaccines and what a successful vaccine would look like, but there have been notable advances in our understanding of how long-lasting protective immunity to pathogens develop. Moving forward, the field will benefit from this new understanding as well as of a more comprehensive characterization of T cell-mediated immunity to <italic toggle="yes">S. aureus</italic>, especially after secondary infections. This knowledge should provide a framework for the development of strategies to mitigate the manipulation of adaptive immunity by <italic toggle="yes">S. aureus</italic>, and thus inform the development of novel and efficacious vaccines. Clarifying if natural infection with <italic toggle="yes">S. aureus</italic> leads to the differentiation of antigen-specific T<sub>RM</sub> and their potential function (or disfunction) in both experimental models and in patients is just one of the many aspects that will contribute to the development of a protective vaccine against <italic toggle="yes">S. aureus</italic>. The development of new tools that facilitate the characterization of the <italic toggle="yes">S. aureus</italic>-specific T cell responses, such as <italic toggle="yes">S. aureus</italic>-specific TCR transgenic mice, will also greatly benefit the field.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to the members of the Martins and Liu labs for discussions.</p></ack><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Writing&#8212;original draft preparation and editing, E.I.A.; writing&#8212;review and editing, G.Y.L.; writing&#8212;review and editing, G.A.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by NIH research grant 2R01AI103542-06 and 1R21AI151987 (to G.A.M.), R01AI144694-01 (to G.Y.L.), R01 AI127406 (to G.Y.L. and G.A.M.) and by internal funds from the Biological Sciences Dept. CSMC (to G.A.M.).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-microorganisms-08-01936"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Sexton</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kanafani</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Auten</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>K.S.</given-names></name></person-group><article-title>Severe surgical site infection in community hospitals: Epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus</article-title><source>Infect. Control. Hosp. Epidemiol.</source><year>2007</year><volume>28</volume><fpage>1047</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1086/520731</pub-id><pub-id pub-id-type="pmid">17932825</pub-id></element-citation></ref><ref id="B2-microorganisms-08-01936"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berr&#237;os-Torres</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Umscheid</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Bratzler</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Leas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Kelz</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Reinke</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Solomkin</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Mazuki</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection</article-title><source>JAMA Surg.</source><year>2017</year><volume>152</volume><fpage>784</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1001/jamasurg.2017.0904</pub-id><pub-id pub-id-type="pmid">28467526</pub-id></element-citation></ref><ref id="B3-microorganisms-08-01936"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name></person-group><article-title>Comparison of community- and healthcare-associated methicillin-resistant Staphylococcus aureus isolates at a Chinese tertiary hospital, 2012&#8211;2017</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>17916</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-36206-5</pub-id><pub-id pub-id-type="pmid">30559468</pub-id><pub-id pub-id-type="pmcid">PMC6297250</pub-id></element-citation></ref><ref id="B4-microorganisms-08-01936"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name><name name-style="western"><surname>David</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Bartsch</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Slayton</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Macal</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Lauderdale</surname><given-names>D.S.</given-names></name><etal/></person-group><article-title>The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)</article-title><source>Clin. Microbiol. Infect.</source><year>2013</year><volume>19</volume><fpage>528</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2012.03914.x</pub-id><pub-id pub-id-type="pmid">22712729</pub-id><pub-id pub-id-type="pmcid">PMC3463640</pub-id></element-citation></ref><ref id="B5-microorganisms-08-01936"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acton</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Plat-Sinnige</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>van Wamel</surname><given-names>W.</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>N.</given-names></name><name name-style="western"><surname>van Belkum</surname><given-names>A.</given-names></name></person-group><article-title>Intestinal carriage of Staphylococcus aureus: How does its frequency compare with that of nasal carriage and what is its clinical impact?</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2009</year><volume>28</volume><fpage>115</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1007/s10096-008-0602-7</pub-id><pub-id pub-id-type="pmid">18688664</pub-id></element-citation></ref><ref id="B6-microorganisms-08-01936"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Belkum</surname><given-names>A.</given-names></name><name name-style="western"><surname>Verkaik</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>de Vogel</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Boelens</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Verveer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nouwen</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Verbrugh</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Wertheim</surname><given-names>H.F.</given-names></name></person-group><article-title>Reclassification of Staphylococcus aureus nasal carriage types</article-title><source>J. Infect. Dis.</source><year>2009</year><volume>199</volume><fpage>1820</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.1086/599119</pub-id><pub-id pub-id-type="pmid">19419332</pub-id></element-citation></ref><ref id="B7-microorganisms-08-01936"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jimenez-Truque</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tedeschi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saye</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Langdon</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Alsentzer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saville</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Relationship between maternal and neonatal Staphylococcus aureus colonization</article-title><source>Pediatrics</source><year>2012</year><volume>129</volume><fpage>e1252-9</fpage><pub-id pub-id-type="doi">10.1542/peds.2011-2308</pub-id><pub-id pub-id-type="pmid">22473373</pub-id><pub-id pub-id-type="pmcid">PMC3340589</pub-id></element-citation></ref><ref id="B8-microorganisms-08-01936"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Diep</surname><given-names>B.A.</given-names></name></person-group><article-title>Clinical practice: Colonization, fomites, and virulence: Rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection</article-title><source>Clin. Infect. Dis.</source><year>2008</year><volume>46</volume><fpage>752</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1086/526773</pub-id><pub-id pub-id-type="pmid">18220477</pub-id></element-citation></ref><ref id="B9-microorganisms-08-01936"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skinner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Keefer</surname><given-names>S.C.</given-names></name></person-group><article-title>Significance of bacteremia caused by staphylococcus aureus: A study of one hundred and twenty-two cases and a review of the literature concerned with experimental infection in animals</article-title><source>Arch. Intern. Med.</source><year>1941</year><volume>68</volume><fpage>851</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1001/archinte.1941.00200110003001</pub-id></element-citation></ref><ref id="B10-microorganisms-08-01936"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Hal</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Vaska</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Espedido</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Gosbell</surname><given-names>I.B.</given-names></name></person-group><article-title>Predictors of mortality in Staphylococcus aureus Bacteremia</article-title><source>Clin. Microbiol. Rev.</source><year>2012</year><volume>25</volume><fpage>362</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1128/CMR.05022-11</pub-id><pub-id pub-id-type="pmid">22491776</pub-id><pub-id pub-id-type="pmcid">PMC3346297</pub-id></element-citation></ref><ref id="B11-microorganisms-08-01936"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kopp</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Nix</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>E.P.</given-names></name></person-group><article-title>Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections</article-title><source>Ann. Pharm.</source><year>2004</year><volume>38</volume><fpage>1377</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.1345/aph.1E028</pub-id><pub-id pub-id-type="pmid">15266044</pub-id></element-citation></ref><ref id="B12-microorganisms-08-01936"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giersing</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Dastgheyb</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Modjarrad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moorthy</surname><given-names>V.</given-names></name></person-group><article-title>Status of vaccine research and development of vaccines for Staphylococcus aureus</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>2962</fpage><lpage>2966</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.03.110</pub-id><pub-id pub-id-type="pmid">27105559</pub-id></element-citation></ref><ref id="B13-microorganisms-08-01936"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Raffaelli</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Rossetti</surname><given-names>B.</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Montagnani</surname><given-names>F.</given-names></name></person-group><article-title>Staphylococcus aureus vaccine preclinical and clinical development: Current state of the art</article-title><source>N. Microbiol.</source><year>2018</year><volume>41</volume><fpage>208</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">29874390</pub-id></element-citation></ref><ref id="B14-microorganisms-08-01936"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fowler</surname><given-names>V.G.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Proctor</surname><given-names>R.A.</given-names></name></person-group><article-title>Where does a Staphylococcus aureus vaccine stand?</article-title><source>Clin. Microbiol. Infect.</source><year>2014</year><volume>20</volume><issue>Suppl. S5</issue><fpage>66</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1111/1469-0691.12570</pub-id><pub-id pub-id-type="pmid">24476315</pub-id><pub-id pub-id-type="pmcid">PMC4067250</pub-id></element-citation></ref><ref id="B15-microorganisms-08-01936"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Donald</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Scully</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Nanra</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K.U.</given-names></name></person-group><article-title>Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors</article-title><source>Hum. Vaccines Immunother.</source><year>2012</year><volume>8</volume><fpage>1585</fpage><lpage>1594</lpage><pub-id pub-id-type="doi">10.4161/hv.21872</pub-id><pub-id pub-id-type="pmid">22922765</pub-id><pub-id pub-id-type="pmcid">PMC3601133</pub-id></element-citation></ref><ref id="B16-microorganisms-08-01936"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagnoli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grandi</surname><given-names>G.</given-names></name></person-group><article-title>Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials</article-title><source>Front. Cell Infect. Microbiol.</source><year>2012</year><volume>2</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2012.00016</pub-id><pub-id pub-id-type="pmid">22919608</pub-id><pub-id pub-id-type="pmcid">PMC3417391</pub-id></element-citation></ref><ref id="B17-microorganisms-08-01936"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Grumann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tr&#252;be</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pritchett-Corning</surname><given-names>K.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reppschl&#228;ger</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gumz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sundaramoorthy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Michalik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Laboratory Mice Are Frequently Colonized with Staphylococcus aureus and Mount a Systemic Immune Response-Note of Caution for In vivo Infection Experiments</article-title><source>Front. Cell Infect. Microbiol.</source><year>2017</year><volume>7</volume><fpage>152</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2017.00152</pub-id><pub-id pub-id-type="pmid">28512627</pub-id><pub-id pub-id-type="pmcid">PMC5411432</pub-id></element-citation></ref><ref id="B18-microorganisms-08-01936"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pritchett-Corning</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Cosentino</surname><given-names>J.</given-names></name><name name-style="western"><surname>Clifford</surname><given-names>C.B.</given-names></name></person-group><article-title>Contemporary prevalence of infectious agents in laboratory mice and rats</article-title><source>Lab. Anim.</source><year>2009</year><volume>43</volume><fpage>165</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1258/la.2008.008009</pub-id><pub-id pub-id-type="pmid">19015179</pub-id></element-citation></ref><ref id="B19-microorganisms-08-01936"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benjamin</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Schelonka</surname><given-names>R.</given-names></name><name name-style="western"><surname>White</surname><given-names>R.</given-names></name><name name-style="western"><surname>Holley</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Bifano</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adcock</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Puppala</surname><given-names>B.</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin</article-title><source>J. Perinatol.</source><year>2006</year><volume>26</volume><fpage>290</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1038/sj.jp.7211496</pub-id><pub-id pub-id-type="pmid">16598296</pub-id></element-citation></ref><ref id="B20-microorganisms-08-01936"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rupp</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Holley</surname><given-names>H.P.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Lutz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dicpinigaitis</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Veney</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>V.G.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia</article-title><source>Antimicrob. Agents Chemother.</source><year>2007</year><volume>51</volume><fpage>4249</fpage><lpage>4254</lpage><pub-id pub-id-type="doi">10.1128/AAC.00570-07</pub-id><pub-id pub-id-type="pmid">17893153</pub-id><pub-id pub-id-type="pmcid">PMC2168017</pub-id></element-citation></ref><ref id="B21-microorganisms-08-01936"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeJonge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burchfield</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>B.</given-names></name><name name-style="western"><surname>Duenas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>W.</given-names></name><name name-style="western"><surname>Polak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>E.</given-names></name><name name-style="western"><surname>Millard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schelonka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Eyal</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants</article-title><source>J. Pediatr.</source><year>2007</year><volume>151</volume><fpage>260</fpage><lpage>265.e1</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2007.04.060</pub-id><pub-id pub-id-type="pmid">17719934</pub-id></element-citation></ref><ref id="B22-microorganisms-08-01936"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weems</surname><given-names>J.J.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Steinberg</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Filler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baddley</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Corey</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Sampathkumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Winston</surname><given-names>L.</given-names></name><name name-style="western"><surname>John</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Kubin</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Talwani</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia</article-title><source>Antimicrob. Agents Chemother.</source><year>2006</year><volume>50</volume><fpage>2751</fpage><lpage>2755</lpage><pub-id pub-id-type="doi">10.1128/AAC.00096-06</pub-id><pub-id pub-id-type="pmid">16870768</pub-id><pub-id pub-id-type="pmcid">PMC1538656</pub-id></element-citation></ref><ref id="B23-microorganisms-08-01936"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magyarics</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bartko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rouha</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luperchio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sch&#246;rgenhofer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schwameis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Derhaschnig</surname><given-names>U.</given-names></name><name name-style="western"><surname>Lagler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stiebellehner</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><fpage>e00350-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.00350-19</pub-id><pub-id pub-id-type="pmid">31138568</pub-id><pub-id pub-id-type="pmcid">PMC6658777</pub-id></element-citation></ref><ref id="B24-microorganisms-08-01936"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weisman</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Thackray</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Steinhorn</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Lassiter</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Dhanireddy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brozanski</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Trautman</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Escobedo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis</article-title><source>Pediatrics</source><year>2011</year><volume>128</volume><fpage>271</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1542/peds.2010-3081</pub-id><pub-id pub-id-type="pmid">21788224</pub-id></element-citation></ref><ref id="B25-microorganisms-08-01936"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Robbie</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Esse</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Bellamy</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hernandez-Illas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jafri</surname><given-names>H.S.</given-names></name></person-group><article-title>Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><fpage>e01020-16</fpage><pub-id pub-id-type="doi">10.1128/AAC.01020-16</pub-id><pub-id pub-id-type="pmid">27795368</pub-id><pub-id pub-id-type="pmcid">PMC5192133</pub-id></element-citation></ref><ref id="B26-microorganisms-08-01936"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fran&#231;ois</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mercier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Asehnoune</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nseir</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fiancette</surname><given-names>M.</given-names></name><name name-style="western"><surname>Desachy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Plantef&#232;ve</surname><given-names>G.</given-names></name><name name-style="western"><surname>Meziani</surname><given-names>F.</given-names></name><name name-style="western"><surname>de Lame</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: First-in-human trial</article-title><source>Intensive Care Med.</source><year>2018</year><volume>44</volume><fpage>1787</fpage><lpage>1796</lpage><pub-id pub-id-type="doi">10.1007/s00134-018-5229-2</pub-id><pub-id pub-id-type="pmid">30343314</pub-id></element-citation></ref><ref id="B27-microorganisms-08-01936"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fowler</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Moustafa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Isgro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Corey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carmeli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Betts</surname><given-names>R.</given-names></name><name name-style="western"><surname>Harzel</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: A randomized trial</article-title><source>JAMA</source><year>2013</year><volume>309</volume><fpage>1368</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.3010</pub-id><pub-id pub-id-type="pmid">23549582</pub-id></element-citation></ref><ref id="B28-microorganisms-08-01936"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNeely</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Fridman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hartzel</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Keshari</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Lupu</surname><given-names>F.</given-names></name><name name-style="western"><surname>DiNubile</surname><given-names>M.J.</given-names></name></person-group><article-title>Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: An analysis of possible contributing host factors</article-title><source>Hum. Vaccines Immunother.</source><year>2014</year><volume>10</volume><fpage>3513</fpage><lpage>3516</lpage><pub-id pub-id-type="doi">10.4161/hv.34407</pub-id><pub-id pub-id-type="pmcid">PMC4514053</pub-id><pub-id pub-id-type="pmid">25483690</pub-id></element-citation></ref><ref id="B29-microorganisms-08-01936"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aman</surname><given-names>M.J.</given-names></name></person-group><article-title>Integrated BioTherapeutics</article-title><source>Hum. Vaccines Immunother.</source><year>2018</year><volume>14</volume><fpage>1308</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1440105</pub-id><pub-id pub-id-type="pmcid">PMC6037449</pub-id><pub-id pub-id-type="pmid">29641293</pub-id></element-citation></ref><ref id="B30-microorganisms-08-01936"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Landrum</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Lalani</surname><given-names>T.</given-names></name><name name-style="western"><surname>Niknian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Hospenthal</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Fattom</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wilkins</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a recombinant Staphylococcus aureus &#945;-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults</article-title><source>Hum. Vaccines Immunother.</source><year>2017</year><volume>13</volume><fpage>791</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1248326</pub-id><pub-id pub-id-type="pmcid">PMC5404372</pub-id><pub-id pub-id-type="pmid">28010246</pub-id></element-citation></ref><ref id="B31-microorganisms-08-01936"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Pasetti</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Baughman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>R.</given-names></name><name name-style="western"><surname>El-Khorazaty</surname><given-names>J.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Holtsberg</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Reymann</surname><given-names>M.K.</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax</article-title><source>Clin. Vaccines Immunol.</source><year>2016</year><volume>23</volume><fpage>918</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1128/CVI.00399-16</pub-id><pub-id pub-id-type="pmid">27707765</pub-id><pub-id pub-id-type="pmcid">PMC5139602</pub-id></element-citation></ref><ref id="B32-microorganisms-08-01936"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>White</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Filler</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yeaman</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Hennessey</surname><given-names>J.P.</given-names><suffix>Jr.</suffix></name></person-group><article-title>NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>7594</fpage><lpage>7600</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.038</pub-id><pub-id pub-id-type="pmid">23099329</pub-id><pub-id pub-id-type="pmcid">PMC3513491</pub-id></element-citation></ref><ref id="B33-microorganisms-08-01936"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Begier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Baber</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sabharwal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Haupt</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K.U.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>A.S.</given-names></name></person-group><article-title>The development of a staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery</article-title><source>Hum. Vaccines Immunother.</source><year>2019</year><volume>15</volume><fpage>358</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1523093</pub-id><pub-id pub-id-type="pmid">30215582</pub-id><pub-id pub-id-type="pmcid">PMC6422482</pub-id></element-citation></ref><ref id="B34-microorganisms-08-01936"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fattom</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matalon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buerkert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>K.</given-names></name><name name-style="western"><surname>Damaso</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boutriau</surname><given-names>D.</given-names></name></person-group><article-title>Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study</article-title><source>Hum. Vaccines Immunother.</source><year>2015</year><volume>11</volume><fpage>632</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.4161/hv.34414</pub-id><pub-id pub-id-type="pmcid">PMC4514248</pub-id><pub-id pub-id-type="pmid">25483694</pub-id></element-citation></ref><ref id="B35-microorganisms-08-01936"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fattom</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Horwith</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Propst</surname><given-names>M.</given-names></name><name name-style="western"><surname>Naso</surname><given-names>R.</given-names></name></person-group><article-title>Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: From the lab bench to phase III clinical trials</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>880</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.11.034</pub-id><pub-id pub-id-type="pmid">15040941</pub-id></element-citation></ref><ref id="B36-microorganisms-08-01936"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spaan</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Surewaard</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Nijland</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Strijp</surname><given-names>J.A.</given-names></name></person-group><article-title>Neutrophils versus Staphylococcus aureus: A biological tug of war</article-title><source>Annu. Rev. Microbiol.</source><year>2013</year><volume>67</volume><fpage>629</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-092412-155746</pub-id><pub-id pub-id-type="pmid">23834243</pub-id></element-citation></ref><ref id="B37-microorganisms-08-01936"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomsen</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.Y.</given-names></name></person-group><article-title>Targeting fundamental pathways to disrupt Staphylococcus aureus survival: Clinical implications of recent discoveries</article-title><source>JCI Insight</source><year>2018</year><volume>3</volume><fpage>e98216</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.98216</pub-id><pub-id pub-id-type="pmcid">PMC5922289</pub-id><pub-id pub-id-type="pmid">29515041</pub-id></element-citation></ref><ref id="B38-microorganisms-08-01936"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deshmukh</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Hamburger</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>McCafferty</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>V.G.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Critical role of NOD2 in regulating the immune response to Staphylococcus aureus</article-title><source>Infect. Immun.</source><year>2009</year><volume>77</volume><fpage>1376</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.1128/IAI.00940-08</pub-id><pub-id pub-id-type="pmid">19139201</pub-id><pub-id pub-id-type="pmcid">PMC2663139</pub-id></element-citation></ref><ref id="B39-microorganisms-08-01936"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pietras</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Shahangian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Thirumala</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Modlin</surname><given-names>R.L.</given-names></name></person-group><article-title>MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus</article-title><source>Immunity</source><year>2006</year><volume>24</volume><fpage>79</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2005.11.011</pub-id><pub-id pub-id-type="pmid">16413925</pub-id></element-citation></ref><ref id="B40-microorganisms-08-01936"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hoshino</surname><given-names>K.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection</article-title><source>J. Immunol.</source><year>2000</year><volume>165</volume><fpage>5392</fpage><lpage>5396</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.165.10.5392</pub-id><pub-id pub-id-type="pmid">11067888</pub-id></element-citation></ref><ref id="B41-microorganisms-08-01936"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ku</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>von Bernuth</surname><given-names>H.</given-names></name><name name-style="western"><surname>Picard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chrabieh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Issekutz</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Gallin</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity</article-title><source>J. Exp. Med.</source><year>2007</year><volume>204</volume><fpage>2407</fpage><lpage>2422</lpage><pub-id pub-id-type="doi">10.1084/jem.20070628</pub-id><pub-id pub-id-type="pmid">17893200</pub-id><pub-id pub-id-type="pmcid">PMC2118442</pub-id></element-citation></ref><ref id="B42-microorganisms-08-01936"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Puel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bonnet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ku</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Bustamante</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Soudais</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dupuis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Feinberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fieschi</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Pyogenic bacterial infections in humans with IRAK-4 deficiency</article-title><source>Science</source><year>2003</year><volume>299</volume><fpage>2076</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1126/science.1081902</pub-id><pub-id pub-id-type="pmid">12637671</pub-id></element-citation></ref><ref id="B43-microorganisms-08-01936"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picard</surname><given-names>C.</given-names></name><name name-style="western"><surname>von Bernuth</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ghandil</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chrabieh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>O.</given-names></name><name name-style="western"><surname>Arkwright</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>D.</given-names></name><name name-style="western"><surname>Geha</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Takada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Krause</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency</article-title><source>Medicine</source><year>2010</year><volume>89</volume><fpage>403</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1097/MD.0b013e3181fd8ec3</pub-id><pub-id pub-id-type="pmid">21057262</pub-id><pub-id pub-id-type="pmcid">PMC3103888</pub-id></element-citation></ref><ref id="B44-microorganisms-08-01936"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Bernuth</surname><given-names>H.</given-names></name><name name-style="western"><surname>Picard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pankla</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ku</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Chrabieh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mustapha</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Ghandil</surname><given-names>P.</given-names></name><name name-style="western"><surname>Camcioglu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Pyogenic bacterial infections in humans with MyD88 deficiency</article-title><source>Science</source><year>2008</year><volume>321</volume><fpage>691</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1126/science.1158298</pub-id><pub-id pub-id-type="pmid">18669862</pub-id><pub-id pub-id-type="pmcid">PMC2688396</pub-id></element-citation></ref><ref id="B45-microorganisms-08-01936"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fournier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Philpott</surname><given-names>D.J.</given-names></name></person-group><article-title>Recognition of Staphylococcus aureus by the innate immune system</article-title><source>Clin. Microbiol. Rev.</source><year>2005</year><volume>18</volume><fpage>521</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1128/CMR.18.3.521-540.2005</pub-id><pub-id pub-id-type="pmid">16020688</pub-id><pub-id pub-id-type="pmcid">PMC1195972</pub-id></element-citation></ref><ref id="B46-microorganisms-08-01936"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>B.</given-names></name><name name-style="western"><surname>Olaniyi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kwiecinski</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wardenburg</surname><given-names>J.B.</given-names></name></person-group><article-title>Staphylococcus aureus toxin suppresses antigen-specific T cell responses</article-title><source>J. Clin. Investig.</source><year>2020</year><volume>130</volume><fpage>1122</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1172/JCI130728</pub-id><pub-id pub-id-type="pmid">31873074</pub-id><pub-id pub-id-type="pmcid">PMC7269593</pub-id></element-citation></ref><ref id="B47-microorganisms-08-01936"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrews</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>K.E.</given-names></name></person-group><article-title>Infections in patients with inherited defects in phagocytic function</article-title><source>Clin. Microbiol. Rev.</source><year>2003</year><volume>16</volume><fpage>597</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1128/CMR.16.4.597-621.2003</pub-id><pub-id pub-id-type="pmid">14557288</pub-id><pub-id pub-id-type="pmcid">PMC207096</pub-id></element-citation></ref><ref id="B48-microorganisms-08-01936"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ancliff</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Thrasher</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>S.O.</given-names></name></person-group><article-title>Recent advances in the understanding of genetic defects of neutrophil number and function</article-title><source>Br. J. Haematol.</source><year>2010</year><volume>151</volume><fpage>312</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2010.08361.x</pub-id><pub-id pub-id-type="pmid">20813010</pub-id></element-citation></ref><ref id="B49-microorganisms-08-01936"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Barca</surname><given-names>E.</given-names></name><name name-style="western"><surname>Carratal&#224;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mykietiuk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Sevilla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gudiol</surname><given-names>F.</given-names></name></person-group><article-title>Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2001</year><volume>20</volume><fpage>117</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1007/PL00011241</pub-id><pub-id pub-id-type="pmid">11305464</pub-id></element-citation></ref><ref id="B50-microorganisms-08-01936"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakshman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Finn</surname><given-names>A.</given-names></name></person-group><article-title>Neutrophil disorders and their management</article-title><source>J. Clin. Pathol.</source><year>2001</year><volume>54</volume><fpage>7</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1136/jcp.54.1.7</pub-id><pub-id pub-id-type="pmid">11271792</pub-id><pub-id pub-id-type="pmcid">PMC1731272</pub-id></element-citation></ref><ref id="B51-microorganisms-08-01936"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Kristian</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Weidenmaier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Faigle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Kessel</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Van Strijp</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>G&#246;tz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Neumeister</surname><given-names>B.</given-names></name><name name-style="western"><surname>Peschel</surname><given-names>A.</given-names></name></person-group><article-title>Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice</article-title><source>J. Infect. Dis.</source><year>2002</year><volume>186</volume><fpage>214</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1086/341454</pub-id><pub-id pub-id-type="pmid">12134257</pub-id></element-citation></ref><ref id="B52-microorganisms-08-01936"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Essex</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Bastian</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Fierer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nizet</surname><given-names>V.</given-names></name></person-group><article-title>Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity</article-title><source>J. Exp. Med.</source><year>2005</year><volume>202</volume><fpage>209</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1084/jem.20050846</pub-id><pub-id pub-id-type="pmid">16009720</pub-id><pub-id pub-id-type="pmcid">PMC2213009</pub-id></element-citation></ref><ref id="B53-microorganisms-08-01936"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thammavongsa</surname><given-names>V.</given-names></name><name name-style="western"><surname>Missiakas</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Schneewind</surname><given-names>O.</given-names></name></person-group><article-title>Staphylococcus aureus degrades neutrophil extracellular traps to promote immune cell death</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>863</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1126/science.1242255</pub-id><pub-id pub-id-type="pmid">24233725</pub-id><pub-id pub-id-type="pmcid">PMC4026193</pub-id></element-citation></ref><ref id="B54-microorganisms-08-01936"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kolar</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Singhania</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Carvalho</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Arditi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Underhill</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>O-Acetylation of Peptidoglycan Limits Helper T Cell Priming and Permits Staphylococcus aureus Reinfection</article-title><source>Cell Host Microbe</source><year>2017</year><volume>22</volume><fpage>543</fpage><lpage>551.e4</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.08.008</pub-id><pub-id pub-id-type="pmid">28943328</pub-id><pub-id pub-id-type="pmcid">PMC5679255</pub-id></element-citation></ref><ref id="B55-microorganisms-08-01936"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero Pastrana</surname><given-names>F.</given-names></name><name name-style="western"><surname>Neef</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koedijk</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Graaf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Duipmans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jonkman</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Engelmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Dijl</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Buist</surname><given-names>G.</given-names></name></person-group><article-title>Human antibody responses against non-covalently cell wall-bound Staphylococcus aureus proteins</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>3234</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-21724-z</pub-id><pub-id pub-id-type="pmid">29459694</pub-id><pub-id pub-id-type="pmcid">PMC5818649</pub-id></element-citation></ref><ref id="B56-microorganisms-08-01936"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stolz</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Vergeront</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Crass</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Chesney</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Wand</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Bergdoll</surname><given-names>M.S.</given-names></name></person-group><article-title>Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin</article-title><source>J. Infect. Dis.</source><year>1985</year><volume>151</volume><fpage>883</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1093/infdis/151.5.883</pub-id><pub-id pub-id-type="pmid">3989322</pub-id></element-citation></ref><ref id="B57-microorganisms-08-01936"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Akhgar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sellman</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Roskos</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Esser</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Ruzin</surname><given-names>A.</given-names></name></person-group><article-title>Prevalence of IgG and Neutralizing Antibodies against Staphylococcus aureus Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations</article-title><source>Infect. Immun.</source><year>2018</year><volume>86</volume><fpage>e00671-17</fpage><pub-id pub-id-type="pmid">29263109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00671-17</pub-id><pub-id pub-id-type="pmcid">PMC5820940</pub-id></element-citation></ref><ref id="B58-microorganisms-08-01936"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thammavongsa</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Missiakas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schneewind</surname><given-names>O.</given-names></name></person-group><article-title>Staphylococcal manipulation of host immune responses</article-title><source>Nat. Rev. Microbiol.</source><year>2015</year><volume>13</volume><fpage>529</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3521</pub-id><pub-id pub-id-type="pmid">26272408</pub-id><pub-id pub-id-type="pmcid">PMC4625792</pub-id></element-citation></ref><ref id="B59-microorganisms-08-01936"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodyear</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>G.J.</given-names></name></person-group><article-title>Death by a B cell superantigen: In vivo VH-targeted apoptotic supraclonal B cell deletion by a Staphylococcal Toxin</article-title><source>J. Exp. Med.</source><year>2003</year><volume>197</volume><fpage>1125</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1084/jem.20020552</pub-id><pub-id pub-id-type="pmid">12719481</pub-id><pub-id pub-id-type="pmcid">PMC2193973</pub-id></element-citation></ref><ref id="B60-microorganisms-08-01936"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adhikari</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Ajao</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Aman</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Karauzum</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sarwar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lydecker</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Roghmann</surname><given-names>M.C.</given-names></name></person-group><article-title>Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections</article-title><source>J. Infect. Dis.</source><year>2012</year><volume>206</volume><fpage>915</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis462</pub-id><pub-id pub-id-type="pmid">22807524</pub-id></element-citation></ref><ref id="B61-microorganisms-08-01936"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritz</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Tiemann</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Epplin</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Al-Zubeidi</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Bubeck Wardenburg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hunstad</surname><given-names>D.A.</given-names></name></person-group><article-title>A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection</article-title><source>Clin. Infect. Dis.</source><year>2013</year><volume>56</volume><fpage>1554</fpage><lpage>1561</lpage><pub-id pub-id-type="doi">10.1093/cid/cit123</pub-id><pub-id pub-id-type="pmid">23446627</pub-id><pub-id pub-id-type="pmcid">PMC3641868</pub-id></element-citation></ref><ref id="B62-microorganisms-08-01936"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Soper</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fallon</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Michell</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Thomsen</surname><given-names>I.</given-names></name></person-group><article-title>Adoptive Transfer of Serum Samples from Children with Invasive Staphylococcal Infection and Protection Against Staphylococcus aureus Sepsis</article-title><source>J. Infect. Dis.</source><year>2020</year><fpage>jiaa482</fpage><pub-id pub-id-type="doi">10.1093/infdis/jiaa482</pub-id><pub-id pub-id-type="pmid">32990305</pub-id><pub-id pub-id-type="pmcid">PMC8030728</pub-id></element-citation></ref><ref id="B63-microorganisms-08-01936"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ledue</surname><given-names>O.</given-names></name><name name-style="western"><surname>Jun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goulart</surname><given-names>C.</given-names></name><name name-style="western"><surname>Malley</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.J.</given-names></name></person-group><article-title>Protection against Staphylococcus aureus Colonization and Infection by B- and T-Cell-Mediated Mechanisms</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e01949-18</fpage><pub-id pub-id-type="doi">10.1128/mBio.01949-18</pub-id><pub-id pub-id-type="pmid">30327437</pub-id><pub-id pub-id-type="pmcid">PMC6191547</pub-id></element-citation></ref><ref id="B64-microorganisms-08-01936"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paterson</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Caldera</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Kolar</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Limon</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Harnessing antifungal immunity in pursuit of a Staphylococcus aureus vaccine strategy</article-title><source>PLoS Pathog.</source><year>2020</year><volume>16</volume><elocation-id>e1008733</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008733</pub-id><pub-id pub-id-type="pmid">32817694</pub-id><pub-id pub-id-type="pmcid">PMC7446838</pub-id></element-citation></ref><ref id="B65-microorganisms-08-01936"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhalla</surname><given-names>F.</given-names></name><name name-style="western"><surname>Misbah</surname><given-names>S.A.</given-names></name></person-group><article-title>Secondary antibody deficiencies</article-title><source>Curr. Opin Allergy Clin. Immunol.</source><year>2015</year><volume>15</volume><fpage>505</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1097/ACI.0000000000000215</pub-id><pub-id pub-id-type="pmid">26406183</pub-id></element-citation></ref><ref id="B66-microorganisms-08-01936"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoernes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reichenbach</surname><given-names>J.</given-names></name></person-group><article-title>Modern management of primary B-cell immunodeficiencies</article-title><source>Pediatr. Allergy Immunol.</source><year>2011</year><volume>22</volume><fpage>758</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1111/j.1399-3038.2011.01236.x</pub-id><pub-id pub-id-type="pmid">22122788</pub-id></element-citation></ref><ref id="B67-microorganisms-08-01936"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Pietras</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Farzam</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Monroe</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Magorien</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Blauvelt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolls</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice</article-title><source>J. Clin. Investif.</source><year>2010</year><volume>120</volume><fpage>1762</fpage><lpage>1773</lpage><pub-id pub-id-type="doi">10.1172/JCI40891</pub-id><pub-id pub-id-type="pmcid">PMC2860944</pub-id><pub-id pub-id-type="pmid">20364087</pub-id></element-citation></ref><ref id="B68-microorganisms-08-01936"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchitto</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Dillen</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Ortines</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Alphonse</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Marusina</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Merleev</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Clonal V&#947;6(+)V&#948;4(+) T cells promote IL-17-mediated immunity against Staphylococcus aureus skin infection</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2019</year><volume>116</volume><fpage>10917</fpage><lpage>10926</lpage><pub-id pub-id-type="doi">10.1073/pnas.1818256116</pub-id><pub-id pub-id-type="pmid">31088972</pub-id><pub-id pub-id-type="pmcid">PMC6561199</pub-id></element-citation></ref><ref id="B69-microorganisms-08-01936"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheridan</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Romagnoli</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>Q.M.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Alonzo</surname><given-names>F.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Schubert</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Freitag</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Lefran&#231;ois</surname><given-names>L.</given-names></name></person-group><article-title>&#947;&#948; T cells exhibit multifunctional and protective memory in intestinal tissues</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>184</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.06.015</pub-id><pub-id pub-id-type="pmid">23890071</pub-id><pub-id pub-id-type="pmcid">PMC3749916</pub-id></element-citation></ref><ref id="B70-microorganisms-08-01936"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luckheeram</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>B.</given-names></name></person-group><article-title>CD4&#8314;T cells: Differentiation and functions</article-title><source>Clin. Dev. Immunol.</source><year>2012</year><volume>2012</volume><fpage>925135</fpage><pub-id pub-id-type="doi">10.1155/2012/925135</pub-id><pub-id pub-id-type="pmid">22474485</pub-id><pub-id pub-id-type="pmcid">PMC3312336</pub-id></element-citation></ref><ref id="B71-microorganisms-08-01936"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowy</surname><given-names>F.D.</given-names></name></person-group><article-title>Is Staphylococcus aureus an intracellular pathogen?</article-title><source>Trends Microbiol.</source><year>2000</year><volume>8</volume><fpage>341</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/S0966-842X(00)01803-5</pub-id><pub-id pub-id-type="pmid">10920387</pub-id></element-citation></ref><ref id="B72-microorganisms-08-01936"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pancari</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cope</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Cua</surname><given-names>D.</given-names></name><name name-style="western"><surname>Proctor</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>McNeely</surname><given-names>T.</given-names></name></person-group><article-title>Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model</article-title><source>Hum. Vaccines Immunother.</source><year>2012</year><volume>8</volume><fpage>336</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.4161/hv.18946</pub-id><pub-id pub-id-type="pmid">22327491</pub-id><pub-id pub-id-type="pmcid">PMC3426080</pub-id></element-citation></ref><ref id="B73-microorganisms-08-01936"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montgomery</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alegre</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Daum</surname><given-names>R.S.</given-names></name></person-group><article-title>Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17A</article-title><source>Infect. Immun.</source><year>2014</year><volume>82</volume><fpage>2125</fpage><lpage>2134</lpage><pub-id pub-id-type="doi">10.1128/IAI.01491-14</pub-id><pub-id pub-id-type="pmid">24614654</pub-id><pub-id pub-id-type="pmcid">PMC3993461</pub-id></element-citation></ref><ref id="B74-microorganisms-08-01936"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Leech</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>McLoughlin</surname><given-names>R.M.</given-names></name></person-group><article-title>The Staphylococcus aureus Map protein is an immunomodulator that interferes with T cell-mediated responses</article-title><source>J. Clin. Investig.</source><year>2002</year><volume>110</volume><fpage>1461</fpage><lpage>1471</lpage><pub-id pub-id-type="doi">10.1172/JCI0216318</pub-id><pub-id pub-id-type="pmid">12438444</pub-id><pub-id pub-id-type="pmcid">PMC151818</pub-id></element-citation></ref><ref id="B75-microorganisms-08-01936"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alonzo</surname><given-names>F.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Kozhaya</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rawlings</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Reyes-Robles</surname><given-names>T.</given-names></name><name name-style="western"><surname>DuMont</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Myszka</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Landau</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Unutmaz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>V.J.</given-names></name></person-group><article-title>CCR5 is a receptor for Staphylococcus aureus leukotoxin ED</article-title><source>Nature</source><year>2013</year><volume>493</volume><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/nature11724</pub-id><pub-id pub-id-type="pmid">23235831</pub-id><pub-id pub-id-type="pmcid">PMC3536884</pub-id></element-citation></ref><ref id="B76-microorganisms-08-01936"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crum-Cianflone</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Grandits</surname><given-names>G.</given-names></name><name name-style="western"><surname>Echols</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ganesan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Landrum</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weintrob</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barthel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Agan</surname><given-names>B.</given-names></name><collab>Infectious Disease Clinical Research Program</collab></person-group><article-title>Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: What is the impact of CD4 counts and HAART use?</article-title><source>J. Acquir Immun. Defic. Syndr.</source><year>2010</year><volume>54</volume><fpage>248</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1097/QAI.0b013e3181c8ef22</pub-id><pub-id pub-id-type="pmcid">PMC2911973</pub-id><pub-id pub-id-type="pmid">20658748</pub-id></element-citation></ref><ref id="B77-microorganisms-08-01936"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manfredi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Calza</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chiodo</surname><given-names>F.</given-names></name></person-group><article-title>Epidemiology and microbiology of cellulitis and bacterial soft tissue infection during HIV disease: A 10-year survey</article-title><source>J. Cutan. Pathol.</source><year>2002</year><volume>29</volume><fpage>168</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0560.2002.290307.x</pub-id><pub-id pub-id-type="pmid">11972714</pub-id></element-citation></ref><ref id="B78-microorganisms-08-01936"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manfredi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Costigliola</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ricchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chiodo</surname><given-names>F.</given-names></name></person-group><article-title>Sepsis-bacteraemia and other infections due to non-opportunistic bacterial pathogens in a consecutive series of 788 patients hospitalized for HIV infection</article-title><source>Clin. Ter.</source><year>1993</year><volume>143</volume><fpage>279</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">8258261</pub-id></element-citation></ref><ref id="B79-microorganisms-08-01936"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beekhuizen</surname><given-names>H.</given-names></name><name name-style="western"><surname>van de Gevel</surname><given-names>J.S.</given-names></name></person-group><article-title>Gamma Interferon Confers Resistance to Infection with <italic toggle="yes">Staphylococcus aureus</italic> in Human Vascular Endothelial Cells by Cooperative Proinflammatory and Enhanced Intrinsic Antibacterial Activities</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>5615</fpage><lpage>5626</lpage><pub-id pub-id-type="doi">10.1128/IAI.00530-07</pub-id><pub-id pub-id-type="pmid">17893127</pub-id><pub-id pub-id-type="pmcid">PMC2168329</pub-id></element-citation></ref><ref id="B80-microorganisms-08-01936"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>A.J.R.</given-names></name><name name-style="western"><surname>Lalor</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>McLoughlin</surname><given-names>R.M.</given-names></name></person-group><article-title>Activation of Human V&#948;2<sup>+</sup> &#947;&#948; T Cells by <italic toggle="yes">Staphylococcus aureus</italic> Promotes Enhanced Anti-Staphylococcal Adaptive Immunity</article-title><source>J. Immunol.</source><year>2020</year><volume>205</volume><fpage>1039</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2000143</pub-id><pub-id pub-id-type="pmid">32651220</pub-id><pub-id pub-id-type="pmcid">PMC7416323</pub-id></element-citation></ref><ref id="B81-microorganisms-08-01936"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Forge</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Billeci</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>S.M.</given-names></name></person-group><article-title>Effect of IFN-gamma on the killing of S. aureus in human whole blood. Assessment of bacterial viability by CFU determination and by a new method using alamarBlue</article-title><source>J. Immunol. Methods</source><year>2000</year><volume>245</volume><fpage>79</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">11042285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-1759(00)00279-9</pub-id></element-citation></ref><ref id="B82-microorganisms-08-01936"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Lalor</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Leech</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>O&#8217;Keeffe</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Mac Aog&#225;in</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Halloran</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Lacey</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Tavakol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hearnden</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1005226</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005226</pub-id><pub-id pub-id-type="pmid">26539822</pub-id><pub-id pub-id-type="pmcid">PMC4634925</pub-id></element-citation></ref><ref id="B83-microorganisms-08-01936"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wakabayashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Iwakura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakane</surname><given-names>A.</given-names></name></person-group><article-title>Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A</article-title><source>Infect. Immun.</source><year>2010</year><volume>78</volume><fpage>4234</fpage><lpage>4242</lpage><pub-id pub-id-type="doi">10.1128/IAI.00447-10</pub-id><pub-id pub-id-type="pmid">20679443</pub-id><pub-id pub-id-type="pmcid">PMC2950370</pub-id></element-citation></ref><ref id="B84-microorganisms-08-01936"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Farber</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Avanesian</surname><given-names>V.</given-names></name><name name-style="western"><surname>Baquir</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>French</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Spellberg</surname><given-names>B.</given-names></name></person-group><article-title>Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice</article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><elocation-id>e1000703</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000703</pub-id><pub-id pub-id-type="pmid">20041174</pub-id><pub-id pub-id-type="pmcid">PMC2792038</pub-id></element-citation></ref><ref id="B85-microorganisms-08-01936"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nurjadi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marcinek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gaile</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heeg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zanger</surname><given-names>P.</given-names></name></person-group><article-title>Ratio of T-Helper Type 1 (Th1) to Th17 Cytokines in Whole Blood Is Associated with Human &#946;-Defensin 3 Expression in Skin and Persistent Staphylococcus aureus Nasal Carriage</article-title><source>J. Infect. Dis.</source><year>2016</year><volume>214</volume><fpage>1744</fpage><lpage>1751</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiw440</pub-id><pub-id pub-id-type="pmid">27651414</pub-id></element-citation></ref><ref id="B86-microorganisms-08-01936"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Chew</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Priyadarshi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grimbacher</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fulcher</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Tangye</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>M.C.</given-names></name></person-group><article-title>Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3</article-title><source>J. Exp. Med.</source><year>2008</year><volume>205</volume><fpage>1551</fpage><lpage>1557</lpage><pub-id pub-id-type="doi">10.1084/jem.20080218</pub-id><pub-id pub-id-type="pmid">18591410</pub-id><pub-id pub-id-type="pmcid">PMC2442632</pub-id></element-citation></ref><ref id="B87-microorganisms-08-01936"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milner</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Brenchley</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Laurence</surname><given-names>A.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Elias</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Kanno</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Spalding</surname><given-names>C.</given-names></name><name name-style="western"><surname>Elloumi</surname><given-names>H.Z.</given-names></name><name name-style="western"><surname>Paulson</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome</article-title><source>Nature</source><year>2008</year><volume>452</volume><fpage>773</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1038/nature06764</pub-id><pub-id pub-id-type="pmid">18337720</pub-id><pub-id pub-id-type="pmcid">PMC2864108</pub-id></element-citation></ref><ref id="B88-microorganisms-08-01936"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renner</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Rylaarsdam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anover-Sombke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rack</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Reichenbach</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carey</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jansson</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Barboza</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schimke</surname><given-names>L.F.</given-names></name><etal/></person-group><article-title>Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome</article-title><source>J. Allergy Clin. Immunol.</source><year>2008</year><volume>122</volume><fpage>181</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2008.04.037</pub-id><pub-id pub-id-type="pmid">18602572</pub-id><pub-id pub-id-type="pmcid">PMC4560358</pub-id></element-citation></ref><ref id="B89-microorganisms-08-01936"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name></person-group><article-title>Staphylococcus aureus induces TGF-&#946;(1) and bFGF expression through the activation of AP-1 and NF-&#954;B transcription factors in bovine mammary epithelial cells</article-title><source>Microb. Pathog.</source><year>2018</year><volume>117</volume><fpage>276</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2018.02.024</pub-id><pub-id pub-id-type="pmid">29452196</pub-id></element-citation></ref><ref id="B90-microorganisms-08-01936"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.X.</given-names></name><name name-style="western"><surname>Guerrero-Juarez</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liggins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Age-Related Loss of Innate Immune Antimicrobial Function of Dermal Fat Is Mediated by Transforming Growth Factor Beta</article-title><source>Immunity</source><year>2019</year><volume>50</volume><fpage>121</fpage><lpage>136.e5</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.11.003</pub-id><pub-id pub-id-type="pmid">30594464</pub-id><pub-id pub-id-type="pmcid">PMC7191997</pub-id></element-citation></ref><ref id="B91-microorganisms-08-01936"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leech</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lacey</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Mulcahy</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>E.</given-names></name><name name-style="western"><surname>McLoughlin</surname><given-names>R.M.</given-names></name></person-group><article-title>IL-10 Plays Opposing Roles during Staphylococcus aureus Systemic and Localized Infections</article-title><source>J. Immunol.</source><year>2017</year><volume>198</volume><fpage>2352</fpage><lpage>2365</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601018</pub-id><pub-id pub-id-type="pmid">28167629</pub-id><pub-id pub-id-type="pmcid">PMC5337812</pub-id></element-citation></ref><ref id="B92-microorganisms-08-01936"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gjertsson</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hultgren</surname><given-names>O.H.</given-names></name><name name-style="western"><surname>Tarkowski</surname><given-names>A.</given-names></name></person-group><article-title>Interleukin-10 ameliorates the outcome of Staphylococcus aureus arthritis by promoting bacterial clearance</article-title><source>Clin. Exp. Immunol.</source><year>2002</year><volume>130</volume><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2249.2002.01999.x</pub-id><pub-id pub-id-type="pmid">12452830</pub-id><pub-id pub-id-type="pmcid">PMC1906560</pub-id></element-citation></ref><ref id="B93-microorganisms-08-01936"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zielinski</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Mele</surname><given-names>F.</given-names></name><name name-style="western"><surname>Aschenbrenner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jarrossay</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ronchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gattorno</surname><given-names>M.</given-names></name><name name-style="western"><surname>Monticelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sallusto</surname><given-names>F.</given-names></name></person-group><article-title>Pathogen-induced human TH17 cells produce IFN-&#947; or IL-10 and are regulated by IL-1&#946;</article-title><source>Nature</source><year>2012</year><volume>484</volume><fpage>514</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/nature10957</pub-id><pub-id pub-id-type="pmid">22466287</pub-id></element-citation></ref><ref id="B94-microorganisms-08-01936"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Berti</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Hayney</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Henriquez</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Ranzoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Proctor</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Nizet</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Increased Endovascular Staphylococcus aureus Inoculum Is the Link Between Elevated Serum Interleukin 10 Concentrations and Mortality in Patients With Bacteremia</article-title><source>Clin. Infect. Dis.</source><year>2017</year><volume>64</volume><fpage>1406</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1093/cid/cix157</pub-id><pub-id pub-id-type="pmid">28205673</pub-id><pub-id pub-id-type="pmcid">PMC5411397</pub-id></element-citation></ref><ref id="B95-microorganisms-08-01936"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebhardt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wakim</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Eidsmo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Reading</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Heath</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>F.R.</given-names></name></person-group><article-title>Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus</article-title><source>Nat. Immunol.</source><year>2009</year><volume>10</volume><fpage>524</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/ni.1718</pub-id><pub-id pub-id-type="pmid">19305395</pub-id></element-citation></ref><ref id="B96-microorganisms-08-01936"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wagers</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Fuhlbrigge</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Kupper</surname><given-names>T.S.</given-names></name></person-group><article-title>Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity</article-title><source>Nature</source><year>2012</year><volume>483</volume><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1038/nature10851</pub-id><pub-id pub-id-type="pmid">22388819</pub-id><pub-id pub-id-type="pmcid">PMC3437663</pub-id></element-citation></ref><ref id="B97-microorganisms-08-01936"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masopust</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vezys</surname><given-names>V.</given-names></name><name name-style="western"><surname>Marzo</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Lefran&#231;ois</surname><given-names>L.</given-names></name></person-group><article-title>Preferential localization of effector memory cells in nonlymphoid tissue</article-title><source>Science</source><year>2001</year><volume>291</volume><fpage>2413</fpage><lpage>2417</lpage><pub-id pub-id-type="doi">10.1126/science.1058867</pub-id><pub-id pub-id-type="pmid">11264538</pub-id></element-citation></ref><ref id="B98-microorganisms-08-01936"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schenkel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Masopust</surname><given-names>D.</given-names></name></person-group><article-title>Tissue-resident memory T cells</article-title><source>Immunity</source><year>2014</year><volume>41</volume><fpage>886</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.12.007</pub-id><pub-id pub-id-type="pmid">25526304</pub-id><pub-id pub-id-type="pmcid">PMC4276131</pub-id></element-citation></ref><ref id="B99-microorganisms-08-01936"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackay</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Macleod</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tebartz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bedoui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Gebhardt</surname><given-names>T.</given-names></name></person-group><article-title>Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention</article-title><source>J. Immunol.</source><year>2015</year><volume>194</volume><fpage>2059</fpage><lpage>2063</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1402256</pub-id><pub-id pub-id-type="pmid">25624457</pub-id></element-citation></ref><ref id="B100-microorganisms-08-01936"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bankovich</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Shiow</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Cyster</surname><given-names>J.G.</given-names></name></person-group><article-title>CD69 suppresses sphingosine 1-phosophate receptor-1 (S1P1) function through interaction with membrane helix 4</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>22328</fpage><lpage>22337</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.123299</pub-id><pub-id pub-id-type="pmid">20463015</pub-id><pub-id pub-id-type="pmcid">PMC2903414</pub-id></element-citation></ref><ref id="B101-microorganisms-08-01936"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skon</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Masopust</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hogquist</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Jameson</surname><given-names>S.C.</given-names></name></person-group><article-title>Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells</article-title><source>Nat. Immunol.</source><year>2013</year><volume>14</volume><fpage>1285</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.1038/ni.2745</pub-id><pub-id pub-id-type="pmid">24162775</pub-id><pub-id pub-id-type="pmcid">PMC3844557</pub-id></element-citation></ref><ref id="B102-microorganisms-08-01936"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Brolin</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Ebert</surname><given-names>E.C.</given-names></name></person-group><article-title>Integrin alpha1beta1 (VLA-1) mediates adhesion of activated intraepithelial lymphocytes to collagen</article-title><source>Immunology</source><year>1999</year><volume>97</volume><fpage>679</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2567.1999.00812.x</pub-id><pub-id pub-id-type="pmid">10457223</pub-id><pub-id pub-id-type="pmcid">PMC2326887</pub-id></element-citation></ref><ref id="B103-microorganisms-08-01936"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackay</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Minnich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kragten</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nota</surname><given-names>B.</given-names></name><name name-style="western"><surname>Seillet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zaid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Man</surname><given-names>K.</given-names></name><name name-style="western"><surname>Preston</surname><given-names>S.</given-names></name><name name-style="western"><surname>Freestone</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes</article-title><source>Science</source><year>2016</year><volume>352</volume><fpage>459</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1126/science.aad2035</pub-id><pub-id pub-id-type="pmid">27102484</pub-id></element-citation></ref><ref id="B104-microorganisms-08-01936"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milner</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Toma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Omilusik</surname><given-names>K.</given-names></name><name name-style="western"><surname>Phan</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Getzler</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Crotty</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Runx3 programs CD8(+) T cell residency in non-lymphoid tissues and tumours</article-title><source>Nature</source><year>2017</year><volume>552</volume><fpage>253</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1038/nature24993</pub-id><pub-id pub-id-type="pmid">29211713</pub-id><pub-id pub-id-type="pmcid">PMC5747964</pub-id></element-citation></ref><ref id="B105-microorganisms-08-01936"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackay</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Wynne-Jones</surname><given-names>E.</given-names></name><name name-style="western"><surname>Freestone</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pellicci</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Mielke</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Masson</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kallies</surname><given-names>A.</given-names></name><name name-style="western"><surname>Belz</surname><given-names>G.T.</given-names></name><etal/></person-group><article-title>T-box Transcription Factors Combine with the Cytokines TGF-&#946; and IL-15 to Control Tissue-Resident Memory T Cell Fate</article-title><source>Immunity</source><year>2015</year><volume>43</volume><fpage>1101</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.11.008</pub-id><pub-id pub-id-type="pmid">26682984</pub-id></element-citation></ref><ref id="B106-microorganisms-08-01936"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nath</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Carbone</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Gebhardt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Inouye</surname><given-names>M.</given-names></name></person-group><article-title>Comparative analysis reveals a role for TGF-&#946; in shaping the residency-related transcriptional signature in tissue-resident memory CD8+ T cells</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0210495</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0210495</pub-id><pub-id pub-id-type="pmid">30742629</pub-id><pub-id pub-id-type="pmcid">PMC6370189</pub-id></element-citation></ref><ref id="B107-microorganisms-08-01936"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bromley</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>&#196;ij&#246;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mora-Buch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carrizosa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Warner</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Hamze</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sen</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Chasse</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Lorant</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Migratory DCs activate TGF-&#946; to precondition na&#239;ve CD8<sup>+</sup> T cells for tissue-resident memory fate</article-title><source>Science</source><year>2019</year><volume>366</volume><fpage>eaav5728</fpage><pub-id pub-id-type="doi">10.1126/science.aav5728</pub-id><pub-id pub-id-type="pmid">31601741</pub-id><pub-id pub-id-type="pmcid">PMC6939608</pub-id></element-citation></ref><ref id="B108-microorganisms-08-01936"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Darrah</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Foulds</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Hoffer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Caffrey-Carr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Norenstedt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perbeck</surname><given-names>L.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Kedl</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>Monocytes Acquire the Ability to Prime Tissue-Resident T Cells via IL-10-Mediated TGF-&#946; Release</article-title><source>Cell Rep.</source><year>2019</year><volume>28</volume><fpage>1127</fpage><lpage>1135.e4</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.06.087</pub-id><pub-id pub-id-type="pmid">31365858</pub-id><pub-id pub-id-type="pmcid">PMC6825402</pub-id></element-citation></ref><ref id="B109-microorganisms-08-01936"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bevan</surname><given-names>M.J.</given-names></name></person-group><article-title>Transforming Growth Factor-&#946; Signaling Controls the Formation and Maintenance of Gut-Resident Memory T Cells by Regulating Migration and Retention</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>687</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.08.019</pub-id><pub-id pub-id-type="pmid">24076049</pub-id><pub-id pub-id-type="pmcid">PMC3805703</pub-id></element-citation></ref><ref id="B110-microorganisms-08-01936"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilk</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Misiak</surname><given-names>A.</given-names></name><name name-style="western"><surname>McManus</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.</given-names></name></person-group><article-title>Lung CD4 Tissue-Resident Memory T Cells Mediate Adaptive Immunity Induced by Previous Infection of Mice with Bordetella pertussis</article-title><source>J. Immunol.</source><year>2017</year><volume>199</volume><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1602051</pub-id><pub-id pub-id-type="pmid">28533445</pub-id></element-citation></ref><ref id="B111-microorganisms-08-01936"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwanaga</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sandquist</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Norton</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Rangel-Moreno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kolls</surname><given-names>J.K.</given-names></name></person-group><article-title><italic toggle="yes">Klebsiella Pneumoniae</italic> Mucosal Vaccination Elicits Lung CD4<sup>+</sup> TRM cells that are resistant to CD4 depleting antibodies</article-title><source>J. Immunol.</source><year>2020</year><volume>204</volume><issue>Suppl. S1</issue><fpage>217</fpage><lpage>234</lpage></element-citation></ref><ref id="B112-microorganisms-08-01936"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stary</surname><given-names>G.</given-names></name><name name-style="western"><surname>Olive</surname><given-names>A.</given-names></name><name name-style="western"><surname>Radovic-Moreno</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Gondek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Basto</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Perro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vrbanac</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Tager</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>aaa8205</fpage><pub-id pub-id-type="doi">10.1126/science.aaa8205</pub-id><pub-id pub-id-type="pmid">26089520</pub-id><pub-id pub-id-type="pmcid">PMC4605428</pub-id></element-citation></ref><ref id="B113-microorganisms-08-01936"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zens</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Farber</surname><given-names>D.L.</given-names></name></person-group><article-title>Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection</article-title><source>JCI Insight</source><year>2016</year><volume>1</volume><fpage>e85832</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.85832</pub-id><pub-id pub-id-type="pmid">27468427</pub-id><pub-id pub-id-type="pmcid">PMC4959801</pub-id></element-citation></ref><ref id="B114-microorganisms-08-01936"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piet</surname><given-names>B.</given-names></name><name name-style="western"><surname>de Bree</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Smids-Dierdorp</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>van der Loos</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Remmerswaal</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>von der Th&#252;sen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>van Haarst</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Eerenberg</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>ten Brinke</surname><given-names>A.</given-names></name><name name-style="western"><surname>van der Bij</surname><given-names>W.</given-names></name><etal/></person-group><article-title>CD8&#8314; T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung</article-title><source>J. Clin. Investig.</source><year>2011</year><volume>121</volume><fpage>2254</fpage><lpage>2263</lpage><pub-id pub-id-type="doi">10.1172/JCI44675</pub-id><pub-id pub-id-type="pmid">21537083</pub-id><pub-id pub-id-type="pmcid">PMC3104744</pub-id></element-citation></ref><ref id="B115-microorganisms-08-01936"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pizzolla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Sant</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jaffar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Loudovaris</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mannering</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Westall</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Kedzierska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wakim</surname><given-names>L.M.</given-names></name></person-group><article-title>Influenza-specific lung-resident memory T cells are proliferative and polyfunctional and maintain diverse TCR profiles</article-title><source>J. Clin. Investig.</source><year>2018</year><volume>128</volume><fpage>721</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1172/JCI96957</pub-id><pub-id pub-id-type="pmid">29309047</pub-id><pub-id pub-id-type="pmcid">PMC5785253</pub-id></element-citation></ref><ref id="B116-microorganisms-08-01936"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Posavad</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Magaret</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wald</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract</article-title><source>Mucosal. Immunol.</source><year>2017</year><volume>10</volume><fpage>1259</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1038/mi.2016.118</pub-id><pub-id pub-id-type="pmid">28051084</pub-id><pub-id pub-id-type="pmcid">PMC5496807</pub-id></element-citation></ref><ref id="B117-microorganisms-08-01936"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Miron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thome</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rak</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Igarashi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Granot</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>H.</given-names></name><name name-style="western"><surname>Goodrum</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Tissue reservoirs of antiviral T cell immunity in persistent human CMV infection</article-title><source>J. Exp. Med.</source><year>2017</year><volume>214</volume><fpage>651</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1084/jem.20160758</pub-id><pub-id pub-id-type="pmid">28130404</pub-id><pub-id pub-id-type="pmcid">PMC5339671</pub-id></element-citation></ref><ref id="B118-microorganisms-08-01936"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jozwik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Paras</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guvenel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dhariwal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Almond</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sykes</surname><given-names>A.</given-names></name><etal/></person-group><article-title>RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>10224</fpage><pub-id pub-id-type="doi">10.1038/ncomms10224</pub-id><pub-id pub-id-type="pmid">26687547</pub-id><pub-id pub-id-type="pmcid">PMC4703893</pub-id></element-citation></ref><ref id="B119-microorganisms-08-01936"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glennie</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Yeramilli</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Beiting</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Volk</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>P.</given-names></name></person-group><article-title>Skin-resident memory CD4+ T cells enhance protection against Leishmania major infection</article-title><source>J. Exp. Med.</source><year>2015</year><volume>212</volume><fpage>1405</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1084/jem.20142101</pub-id><pub-id pub-id-type="pmid">26216123</pub-id><pub-id pub-id-type="pmcid">PMC4548053</pub-id></element-citation></ref><ref id="B120-microorganisms-08-01936"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hobbs</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Osborn</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Nolz</surname><given-names>J.C.</given-names></name></person-group><article-title>Activation and trafficking of CD8(+) T cells during viral skin infection: Immunological lessons learned from vaccinia virus</article-title><source>Curr. Opin. Virol.</source><year>2018</year><volume>28</volume><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2017.10.001</pub-id><pub-id pub-id-type="pmid">29080420</pub-id><pub-id pub-id-type="pmcid">PMC5835170</pub-id></element-citation></ref><ref id="B121-microorganisms-08-01936"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackay</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Rahimpour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stock</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Hafon</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Vega-Ramos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lauzurica</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Stefanovic</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin</article-title><source>Nat. Immunol.</source><year>2013</year><volume>14</volume><fpage>1294</fpage><lpage>1301</lpage><pub-id pub-id-type="doi">10.1038/ni.2744</pub-id><pub-id pub-id-type="pmid">24162776</pub-id></element-citation></ref><ref id="B122-microorganisms-08-01936"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roychoudhury</surname><given-names>P.</given-names></name><name name-style="western"><surname>Swan</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Duke</surname><given-names>E.</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dav&#233;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Spuhler</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Lund</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Prlic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schiffer</surname><given-names>J.T.</given-names></name></person-group><article-title>Tissue-resident T cell-derived cytokines eliminate herpes simplex virus-2-infected cells</article-title><source>J. Clin. Investig.</source><year>2020</year><volume>130</volume><fpage>2903</fpage><lpage>2919</lpage><pub-id pub-id-type="doi">10.1172/JCI132583</pub-id><pub-id pub-id-type="pmid">32125285</pub-id><pub-id pub-id-type="pmcid">PMC7260013</pub-id></element-citation></ref><ref id="B123-microorganisms-08-01936"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linehan</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Byrd</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Vujkovic-Cvijin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Villarino</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Sen</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Shaik</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smelkinson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tamoutounour</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Non-classical Immunity Controls Microbiota Impact on Skin Immunity and Tissue Repair</article-title><source>Cell</source><year>2018</year><volume>172</volume><fpage>784</fpage><lpage>796.e18</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.12.033</pub-id><pub-id pub-id-type="pmid">29358051</pub-id><pub-id pub-id-type="pmcid">PMC6034182</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="microorganisms-08-01936-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The immune response against <italic toggle="yes">S. aureus</italic>. Pattern recognition receptors (TLR2/NOD2/TLR9) expressed on innate immune cells such as macrophages (Mac) and dendritic cells (DC) at the infection site respond to <italic toggle="yes">S. aureus</italic> pathogen-related molecular patterns (LTA, peptidoglycan (PGN), and unmethylated CpG DNA). This interaction leads to the release of cytokines and chemokines (IL-1&#946;, TNF-&#945;, MIP-1&#945;, and GM-CSF), which attracts neutrophils to the site of infection. Neutrophils mediate bacteria killing and clearance via reactive oxygen species (ROS), anti-microbial peptides (AMPs), neutrophil extracellular traps (NETs), and enzymatic digestion by hydrolases and proteinases. After interacting with <italic toggle="yes">S. aureus,</italic> Mac and DC can migrate to draining lymph nodes to present the antigen to na&#239;ve T cells. This interaction causes T cells to undergo functional differentiation, which culminates with the generation of IFN&#947; and IL-17-producing cells. IFN&#947; can activate Mac and DC to enhance antigen presentation (among other inflammatory functions). The expression of IL-17 facilitates neutrophil recruitment. The anti-inflammatory cytokines TGF&#946; and IL-10 can also be induced upon infection and could play both protective (limiting damage) or inhibitory (limiting immune response) roles, depending on the route of infection. Additionally, T<sub>FH</sub> cells could differentiate in response to the initial infection and could interact with B cells so as to foster the production of anti-staphylococcal antibodies that enable the opsonization of bacteria or neutralize staphylococcal toxins.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="microorganisms-08-01936-g001.jpg"/></fig><fig id="microorganisms-08-01936-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>A model for potential roles of T<sub>RM</sub> in protecting against <italic toggle="yes">S. aureus</italic> infection. Given the poor induction of long-lasting protective immunity to <italic toggle="yes">S. aureus</italic> infections, it is possible that natural <italic toggle="yes">S. aureus</italic> infection (broken blue arrows) fails to lead to the development of T<sub>RM</sub> cells. Vaccination strategies (green arrows) proven to induce protective T<sub>RM</sub> responses against another bacterial infection [<xref rid="B112-microorganisms-08-01936" ref-type="bibr">112</xref>] could be employed to promote the induction of protective T<sub>RM</sub> cells. If generated upon vaccination, <italic toggle="yes">S. aureus</italic>-specific T<sub>RM</sub> cells could produce IL-17A and IFN&#947; leading to neutrophil recruitment and subsequent bacterial clearance upon re-infection of sites such as the skin and soft tissues.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="microorganisms-08-01936-g002.jpg"/></fig><table-wrap id="microorganisms-08-01936-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">microorganisms-08-01936-t001_Table 1</object-id><label>Table 1</label><caption><p>Clinical trials of passive <italic toggle="yes">S. aureus</italic> immunization.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Company/ Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Group</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Result</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Dates</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Notes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Citation</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP5/CP8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nabi/ Altastaph</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment of Bacteriemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2002&#8211;2004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shorter length of stay for treatment group. No further development.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rupp et al., 2007 [<xref rid="B20-microorganisms-08-01936" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP5/CP8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nabi/ Altastaph</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevention of invasive infection in very low birth weight neonates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Failed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2003&#8211;2004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No difference between placebo and treatment groups.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benjamin et al., 2006 [<xref rid="B19-microorganisms-08-01936" ref-type="bibr">19</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ClfA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bristol-Myers Squibb/ Aurexis Tefibazumab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment of bacteremia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Failed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No differences between groups.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weems et al., 2006 [<xref rid="B22-microorganisms-08-01936" ref-type="bibr">22</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATP-binding cassette (ABC) transporter GrfA </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neu Tec Pharma/Aurograb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment of deep-seated infection </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Failed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2004&#8211;2006</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No difference between groups</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fowler and Proctor 2015 [<xref rid="B14-microorganisms-08-01936" ref-type="bibr">14</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hla</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AstraZeneca/ Suvratoxumab/ MEDI4893</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mechanically ventilated adults</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Failed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014&#8211;2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No significant differences between groups. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yu et al., 2017 [<xref rid="B25-microorganisms-08-01936" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hla, PVL, LukED, g-hemolysin AB and CB (HlgAB, HlgCB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arsanis Inc/ ASN100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mechanically ventilated subjects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Failed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016&#8211;2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Did not achieve endpoint. Ended in futility.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Magyarics et al., 2019 [<xref rid="B23-microorganisms-08-01936" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ClfA (<italic toggle="yes">S. aureus</italic>) and SdrG (<italic toggle="yes">S. epidermidis</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bristol&#8211;Myers Squibb/ Veronate/ Inhibitex</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sepsis in premature infants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Failed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2004&#8211;2006</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No difference between placebo and treated group.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DeJonge et al., 2007 [<xref rid="B21-microorganisms-08-01936" ref-type="bibr">21</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LTA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biosynexus incorporate/ Pagibmaximab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevention of Sepsis in very low birth weight neonates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Failed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2009&#8211;2011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No significant difference between groups.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weisman et al., 2011 [<xref rid="B24-microorganisms-08-01936" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hla</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aridis Pharmaceuticals/ AR-301</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment of bacterial pneumonia or ventilator-associated pneumonia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019&#8211;2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Promising phase II trials (Francois et al., 2018) [<xref rid="B26-microorganisms-08-01936" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">unpublished</td></tr></tbody></table></table-wrap><table-wrap id="microorganisms-08-01936-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">microorganisms-08-01936-t002_Table 2</object-id><label>Table 2</label><caption><p>Clinical trials of active <italic toggle="yes">S. aureus</italic> immunization.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Company/ Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target Group</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Result</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Dates</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Notes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Citation</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enterotoxin A and C1, TSST, alpha-hemolysin, LukS, LukF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BioTherapeutics/<break/>IBT-V02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-clinical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scheduled to enter phase I clinical trials in 2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aman 2018 [<xref rid="B29-microorganisms-08-01936" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rAT/rLukS-PV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nabi/<break/>N.A.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2009&#8211;2011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No further data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Landrum et al., 2017 [<xref rid="B30-microorganisms-08-01936" ref-type="bibr">30</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant Enterotoxin B (rSEB)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BioTherapeutics/<break/>STEBVax</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011&#8211;2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No further data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chen et al., 2016 [<xref rid="B31-microorganisms-08-01936" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unspecified Recombinant protein&#8212;bioconjugated&#8212;adjuvanted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GSK/<break/>GSK3878858A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020&#8211;2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No data </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unpublished</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Als3p</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NovaDigm Therapeutics/<break/>NDV-3A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nasal colonization (and SSTI) in military personnel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018&#8211;2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Well tolerated in phase I trials and<break/>provided protection against <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">C. albicans</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Schmidt et al., 2012 [<xref rid="B32-microorganisms-08-01936" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CflA/MntC/CP5/CP8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pfizer/<break/>SA-4Ag</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIb/III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elective orthopedic surgery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Failed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015&#8211;2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stopped after sub-par results</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gurtman et al., 2019 [<xref rid="B33-microorganisms-08-01936" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP5/CP8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nabi/<break/>StaphVax</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Renal disease or orthopedic surgery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Failed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2005&#8211;2006</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No difference between placebo and vaccinated groups</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fattom et al., 2004; Fattom et al., 2015 [<xref rid="B34-microorganisms-08-01936" ref-type="bibr">34</xref>,<xref rid="B35-microorganisms-08-01936" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IsdB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Merck/<break/>V710</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevention of infection after cardiothoracic surgery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Failed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2007&#8211;2011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adverse outcomes in vaccinated group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fowler et al., 2013; McNeely et al., 2014 [<xref rid="B26-microorganisms-08-01936" ref-type="bibr">26</xref>,<xref rid="B27-microorganisms-08-01936" ref-type="bibr">27</xref>]</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>